AR226_3287

AR226-3287

TRADE SECRET

Study Title

H-25425: Subchronic Toxicity
90-Day Gavage Study in Rats with One-Generation Reproduction Evaluations

Volume 2 of 5

Laboratory Project ID: DuPont-11418

TEST GUIDELINES: U.S. EPA Health Effects Test Guidelines
OPPTS 870.3100 (AUG-1998)

AUTHOR: Susan A. MacKenzie, V.M.D., Ph.D., D.A.B.T.

STUDY COMPLETED ON: August 1, 2003

PERFORMING LABORATORY: E.I. du Pont de Nemours and Company
Haskell Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050

WORK REQUEST NUMBER: [redacted]

SERVICE CODE NUMBER: [redacted]

Company Sanitized. Does not contain TSCA CBI

TABLE 48

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
LIVER	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED		1		
NECROSIS, FOCAL.				
minimal				1
total observations per lesion				1
INFLAMMATION, SUBACUTE/CHRONIC.				
minimal	10	8	9	9
mild		1	1	1
total observations per lesion	10	9	10	10
HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR.				
minimal				9
total observations per lesion				9
FATTY CHANGE, PERIPORTAL.				
minimal	6	1	3	1
mild	1			
total observations per lesion	7	1	3	1
FATTY CHANGE, MEDIAN CLEFT.				
minimal	2	2	4	1
mild		1	1	
total observations per lesion	2	3	5	1
DEGENERATION, HEPATOCELLULAR, FOCAL.				
mild				1
total observations per lesion				1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
PANCREAS	(10)			(10)
NO ABNORMALITY DETECTED	9			10
INFLAMMATION, FOCAL.				
mild	1			
total observations per lesion	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
ESOPHAGUS	(9)			(10)
NO ABNORMALITY DETECTED	9			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
STOMACH	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
DUODENUM	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
JEJUNUM	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males			
		0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM					
ILEUM		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
CECUM	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
COLON	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
RECTUM	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
SALIVARY GLANDS	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
URINARY SYSTEM				
KIDNEYS	(10)			(9)
NO ABNORMALITY DETECTED	2			1
CHRONIC PROGRESSIVE NEPHROPATHY.				
minimal	7			5
total observations per lesion	7			5
HYDRONEPHROSIS, UNILATERAL.				
mild				1
total observations per lesion				1
CYST, TUBULAR.				
mild				1
total observations per lesion				1
AGGREGATES, LYMPHOID.				
minimal	1			4
total observations per lesion	1			4

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
URINARY SYSTEM				
URINARY BLADDER	(10)			(10)
NO ABNORMALITY DETECTED	8			7
AGGREGATES, LYMPHOID.				
minimal	2			3
total observations per lesion	2			3

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM					
LUNGS		(10)			(10)
NO ABNORMALITY DETECTED		4			4
MACROPHAGES, ALVEOLAR, FOCAL.					
minimal		2			1
total observations per lesion		2			1
INFLAMMATION, SUBACUTE/CHRONIC, PERIVASCULAR.					
minimal		1			3
total observations per lesion		1			3
HEMORRHAGE, ALVEOLAR.					
minimal		2			3
mild		1			
total observations per lesion		3			3

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM				
TRACHEA	(10)			(10)
NO ABNORMALITY DETECTED	10			9
INFLAMMATION, FOCAL.				
minimal				1
total observations per lesion				1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM				
PHARYNX/LARYNX	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM				
NOSE	(10)			(10)
NO ABNORMALITY DETECTED	7			6
INFLAMMATION, TURBINATES.				
minimal				1
mild	1			1
total observations per lesion	1			2
INFLAMMATION, VOMERONASAL ORGAN.				
minimal	1			1
total observations per lesion	1			1
INFLAMMATION, ORAL MUCOSA.				
minimal	1			1
total observations per lesion	1			1
INFLAMMATION, NASOLACRIMAL DUCT.				
mild				1
total observations per lesion				1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
CARDIOVASCULAR SYSTEM				
HEART	(10)			(10)
NO ABNORMALITY DETECTED	9			9
INFLAMMATION, SUBACUTE/CHRONIC.				
minimal	1			1
total observations per lesion	1			1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
CARDIOVASCULAR SYSTEM				
AORTA	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males			
		0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
SPLEEN		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males			
		0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
THYMUS		(10)			(10)
NO ABNORMALITY DETECTED		4			2
HEMORRHAGE.					
minimal		5			7
mild		1			1
total observations per lesion		6			8

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
MANDIBULAR LYMPH NODE	(10)			(10)
NO ABNORMALITY DETECTED	8			6
NECROSIS, LYMPHOID.				
minimal				1
total observations per lesion				1
LEUKOCYTOSIS, PLASMA CELL, MEDULLARY.				
mild	1			1
total observations per lesion	1			1
ERYTHROCYTOSIS/ERYTHROPHAGOCYTOSIS, SINUS.				
minimal	1			
mild				3
total observations per lesion	1			3

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
MESENTERIC LYMPH NODE	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
BONE MARROW	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
ENDOCRINE SYSTEM				
PITUITARY GLAND	(10)			(10)
NO ABNORMALITY DETECTED	9			10
CYST.				
mild	1			
total observations per lesion	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
ENDOCRINE SYSTEM				
THYROID GLAND	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	9	9	9	
HYPERTROPHY, FOLLICULAR CELL.				
minimal		1	1	4
mild	1			6
total observations per lesion	1	1	1	10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
ENDOCRINE SYSTEM				
PARATHYROID GLANDS	(9)			(10)
NO ABNORMALITY DETECTED	9			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
ENDOCRINE SYSTEM					
ADRENAL GLANDS		(10)			(10)
NO ABNORMALITY DETECTED		9			10
ADRENAL MEDULLA MISSING.		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
NERVOUS SYSTEM				
BRAIN	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
NERVOUS SYSTEM				
SPINAL CORD	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
NERVOUS SYSTEM				
SCIATIC NERVE	(9)			(10)
NO ABNORMALITY DETECTED	9			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males			
		0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
MUSCULAR AND SKELETAL SYSTEM					
SKELETAL MUSCLE		(9)			(10)
NO ABNORMALITY DETECTED		9			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
MUSCULAR AND SKELETAL SYSTEM				
FEMUR/KNEE JOINT	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
MUSCULAR AND SKELETAL SYSTEM				
STERNUM	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
TESTES	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
EPIDIDYMIDES	(10)			(10)
NO ABNORMALITY DETECTED	6			5
AGGREGATES, LYMPHOID.				
minimal	4			5
total observations per lesion	4			5

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
PROSTATE	(10)			(10)
NO ABNORMALITY DETECTED	3			4
AGGREGATES, LYMPHOID.				
minimal	7			4
mild				2
total observations per lesion	7			6

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
SEMINAL VESICLES	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
CUTANEOUS SYSTEM				
SKIN	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 48 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
SPECIAL SENSES SYSTEM				
EYE(S) WITH OPTIC NERVE	(10)			(10)
NO ABNORMALITY DETECTED	5			8
OPTIC NERVE NOT PRESENT, UNILATERAL.	4			1
INFLAMMATION, PERIOCULAR, UNILATERAL.				
minimal	4			1
mild				1
total observations per lesion	4			2
ATROPHY, RETINAL, UNILATERAL.				
mild	1			
total observations per lesion	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
LIVER	(10)			(10)
NECROSIS, FOCAL.				
minimal				2
total observations per lesion				2
INFLAMMATION, SUBACUTE/CHRONIC.				
minimal	10			10
total observations per lesion	10			10
FATTY CHANGE, PERIPORTAL.				
minimal	4			2
mild	1			
total observations per lesion	5			2
FATTY CHANGE, MEDIAN CLEFT.				
minimal	2			3
mild	1			2
total observations per lesion	3			5

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM					
PANCREAS		(1)			
FOCUS OF CELLULAR ALTERATION, BASOPHILIC.					
minimal		1			
total observations per lesion		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
ESOPHAGUS	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
STOMACH	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM					
DUODENUM		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
JEJUNUM	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
ILEUM	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
CECUM	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
COLON	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
RECTUM	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
DIGESTIVE SYSTEM				
SALIVARY GLANDS	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

	LESION INCIDENCE (NUMERIC)			
	Males			
LESIONS / TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
URINARY SYSTEM				
KIDNEYS	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
URINARY SYSTEM				
URINARY BLADDER	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM				
LUNGS	(1)			
MACROPHAGES, ALVEOLAR, FOCAL.				
minimal	1			
total observations per lesion	1			
HEMORRHAGE, ALVEOLAR.				
minimal	1			
total observations per lesion	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM				
TRACHEA	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM				
PHARYNX/LARYNX	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Males			
LESIONS	TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
RESPIRATORY SYSTEM					
NOSE		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
CARDIOVASCULAR SYSTEM					
HEART		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
CARDIOVASCULAR SYSTEM					
AORTA		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Males			
LESIONS	TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
SPLEEN		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
THYMUS		(1)			
HEMORRHAGE.					
mild		1			
total observations per lesion		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males			
		0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
MANDIBULAR LYMPH NODE		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
MESENTERIC LYMPH NODE		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
BONE MARROW	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Males 0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
ENDOCRINE SYSTEM					
PITUITARY GLAND		(1)			
NO ABNORMALITY DETECTED		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Males			
LESIONS	TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
ENDOCRINE SYSTEM					
THYROID GLAND		(10)			(10)
NO ABNORMALITY DETECTED		9			4
HYPERTROPHY, FOLLICULAR CELL.					
minimal		1			3
mild					3
total observations per lesion		1			6

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
ENDOCRINE SYSTEM				
ADRENAL GLANDS	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
NERVOUS SYSTEM				
BRAIN				
NO ABNORMALITY DETECTED	(1) 1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
NERVOUS SYSTEM				
SPINAL CORD	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
NERVOUS SYSTEM				
SCIATIC NERVE	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
MUSCULAR AND SKELETAL SYSTEM				
SKELETAL MUSCLE	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
MUSCULAR AND SKELETAL SYSTEM				
FEMUR/KNEE JOINT	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
MUSCULAR AND SKELETAL SYSTEM				
STERNUM	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
TESTES				
NO ABNORMALITY DETECTED	(1) 1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
EPIDIDYMIDES	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
PROSTATE	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
REPRODUCTIVE SYSTEM				
SEMINAL VESICLES	(1)			
NO ABNORMALITY DETECTED	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
CUTANEOUS SYSTEM				
SKIN				
NO ABNORMALITY DETECTED	(1) 1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 49 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Males			
TREATMENT	0 mg/kg I	10 mg/kg III	100 mg/kg V	1000 mg/kg VII
SPECIAL SENSES SYSTEM				
EYE(S) WITH OPTIC NERVE				
OPTIC NERVE NOT PRESENT, UNILATERAL.	(1) 1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM				
LIVER				
NO ABNORMALITY DETECTED	(10)	(10)	(10)	(10)
NECROSIS, FOCAL.	1	2		3
mild			1	
total observations per lesion			1	
INFLAMMATION, SUBACUTE/CHRONIC.				
minimal	8	7	9	7
mild		1	1	
total observations per lesion	8	8	10	7
FATTY CHANGE, PERIPORTAL.				
minimal	6			1
total observations per lesion	6			1
FATTY CHANGE, MEDIAN CLEFT.				
minimal	1			
mild	2	1	1	
total observations per lesion	3	1	1	

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM				
PANCREAS				
NO ABNORMALITY DETECTED	(10)			(10)
AGGREGATES, LYMPHOID.	10			8
minimal				2
total observations per lesion				2

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM				
ESOPHAGUS				
NO ABNORMALITY DETECTED	(10) 10			(10) 10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM				
STOMACH				
NO ABNORMALITY DETECTED	(10) 10			(10) 10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females 0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM					
DUODENUM		(10)			(9)
NO ABNORMALITY DETECTED		10			9

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females			
		0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM					
JEJUNUM		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM				
ILEUM	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM					
CECUM		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females			
		0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM					
COLON		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM					
RECTUM		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females			
		0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
DIGESTIVE SYSTEM					
SALIVARY GLANDS		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females			
		0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
URINARY SYSTEM					
KIDNEYS		(10)			(10)
NO ABNORMALITY DETECTED		6			6
CHRONIC PROGRESSIVE NEPHROPATHY.					
minimal		3			1
total observations per lesion		3			1
AGGREGATES, LYMPHOID.					
minimal		1			2
mild					1
total observations per lesion		1			3

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
URINARY SYSTEM					
URINARY BLADDER		(9)			(10)
NO ABNORMALITY DETECTED		9			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

	LESION INCIDENCE (NUMERIC)			
	Females			
LESIONS / TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
RESPIRATORY SYSTEM				
LUNGS	(10)			(10)
NO ABNORMALITY DETECTED	2			6
INFLAMMATION, SUBACUTE/CHRONIC, PERIVASCULAR.				
minimal	2			1
total observations per lesion	2			1
HEMORRHAGE, ALVEOLAR:				
minimal	7			3
total observations per lesion	7			3

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
RESPIRATORY SYSTEM					
TRACHEA		(10)			(10)
NO ABNORMALITY DETECTED		9			9
INFLAMMATION.					
minimal		1			
total observations per lesion		1			
AGGREGATES, LYMPHOID.					
mild					1
total observations per lesion					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
RESPIRATORY SYSTEM				
PHARYNX/LARYNX	(10)			(10)
NO ABNORMALITY DETECTED	9			10
DEGENERATION, MYOFIBER.				
mild	1			
total observations per lesion	1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
CARDIOVASCULAR SYSTEM				
HEART	(10)			(10)
NO ABNORMALITY DETECTED	10			9
INFLAMMATION, SUBACUTE/CHRONIC.				
minimal				1
total observations per lesion				1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
CARDIOVASCULAR SYSTEM				
AORTA	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
SPLEEN	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
LYMPHATIC AND HEMATOPOIETIC SYSTEM					
THYMUS		(10)			(10)
NO ABNORMALITY DETECTED		5			2
HEMORRHAGE.					
minimal		4			8
mild		1			
total observations per lesion		5			8
CYST, EPITHELIAL.					
mild					1
total observations per lesion					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
MANDIBULAR LYMPH NODE	(10)			(10)
NO ABNORMALITY DETECTED	8			9
LEUKOCYTOSIS, PLASMA CELL, MEDULLARY.				
minimal				1
total observations per lesion				1
HYPERPLASIA, LYMPHOID.				
mild	1			
total observations per lesion	1			
ERYTHROCYTOSIS/ERYTHROPHAGOCYTOSIS, SINUS.				
minimal	1			1
total observations per lesion	1			1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
MESENTERIC LYMPH NODE	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
LYMPHATIC AND HEMATOPOIETIC SYSTEM				
BONE MARROW	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
ENDOCRINE SYSTEM				
PITUITARY GLAND	(10)			(10)
NO ABNORMALITY DETECTED	8			10
CYST.				
minimal	1			
mild	1			
total observations per lesion	2			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
ENDOCRINE SYSTEM				
THYROID GLAND	(10)	(10)	(10)	(10)
NO ABNORMALITY DETECTED	10	10	10	8
HYPERTROPHY, FOLLICULAR CELL.				
minimal				2
total observations per lesion				2

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
ENDOCRINE SYSTEM				
PARATHYROID GLANDS	(8)			(9)
NO ABNORMALITY DETECTED	8			9

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
ENDOCRINE SYSTEM				
ADRENAL GLANDS	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females			
		0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
NERVOUS SYSTEM					
BRAIN		(10)			(10)
NO ABNORMALITY DETECTED		9			10
AGGREGATES, LYMPHOID, CHOROID PLEXUS.					
mild		1			
total observations per lesion		1			

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
NERVOUS SYSTEM				
SPINAL CORD	(9)			(10)
NO ABNORMALITY DETECTED	9			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
NERVOUS SYSTEM				
SCIATIC NERVE	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
MUSCULAR AND SKELETAL SYSTEM				
SKELETAL MUSCLE	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC)			
	Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
MUSCULAR AND SKELETAL SYSTEM				
FEMUR/KNEE JOINT				
NO ABNORMALITY DETECTED	(10) 10			(10) 10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females 0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
MUSCULAR AND SKELETAL SYSTEM					
STERNUM		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

	LESION INCIDENCE (NUMERIC)			
	Females			
LESIONS / TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
REPRODUCTIVE SYSTEM				
OVARIES	(10)			(10)
NO ABNORMALITY DETECTED	10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
REPRODUCTIVE SYSTEM					
UTERUS		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
REPRODUCTIVE SYSTEM					
VAGINA		(10)			(10)
ESTRUS STAGE: METESTRUS.		4			2
ESTRUS STAGE: ESTRUS.		2			3
ESTRUS STAGE: PROESTRUS.		4			5

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
REPRODUCTIVE SYSTEM					
MAMMARY GLAND (FEMALE)		(10)			(10)
NO ABNORMALITY DETECTED		10			10

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

		LESION INCIDENCE (NUMERIC)			
		Females			
LESIONS	TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
CUTANEOUS SYSTEM					
SKIN		(10)			(10)
NO ABNORMALITY DETECTED		9			9
DERMATITIS, FOCAL.					
minimal		1			1
total observations per lesion		1			1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 50 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR SUBCHRONIC TOXICITY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
SPECIAL SENSES SYSTEM				
EYE(S) WITH OPTIC NERVE	(10)			(10)
NO ABNORMALITY DETECTED	8			5
OPTIC NERVE NOT PRESENT, UNILATERAL.	5			4
OPTIC NERVE NOT PRESENT, BILATERAL.	2			1
INFLAMMATION, PERIOCULAR, UNILATERAL.				
minimal	1			4
total observations per lesion	1			4
FOLD/ROSETTE, RETINAL.				
minimal				1
total observations per lesion				1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 51

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
ENDOCRINE SYSTEM				
THYROID GLAND	(10)			(10)
NO ABNORMALITY DETECTED	10			7
HYPERTROPHY, FOLLICULAR CELL.				
minimal				2
total observations per lesion				2
ECTOPIC THYMUS TISSUE.				1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 51 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	TREATMENT	LESION INCIDENCE (NUMERIC) Females 0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
REPRODUCTIVE SYSTEM					
UTERUS					(1)
NO ABNORMALITY DETECTED					1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 51 (CONTINUED)

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS
NON-NEOPLASTIC LESIONS
DESIGNATED FOR RECOVERY EVALUATION

LESIONS	LESION INCIDENCE (NUMERIC) Females			
TREATMENT	0 mg/kg II	10 mg/kg IV	100 mg/kg VI	1000 mg/kg VIII
REPRODUCTIVE SYSTEM				
VAGINA				(1)
ESTRUS STAGE: PROESTRUS.				1

Figure in parentheses is number of animals microscopically examined for this tissue
The absence of a number indicates the lesion specified was not identified

Company Sanitized. Does not contain TSCA CBI

TABLE 52

SUMMARY OF CLINICAL OBSERVATIONS IN P_1 MALE RATS

	NUMBER OF RATS WITH GIVEN SIGN			
GROUP:	I-0	III-0	V-0	VII-0
DOSE (MG/KG/DAY):	0	10	100	1000
NUMBER IN GROUP:	20	20	20	20
OBSERVATIONS				
ALOPECIA	3	2	1	2
COLORED DISCHARGE RIGHT EYE(S)	1	0	0	0
SORE	0	0	1	0

There were no statistically significant trends by Cochran-Armitage trend test; $p < 0.05$.

Company Sanitized. Does not contain TSCA CBI

TABLE 53

SUMMARY OF CLINICAL OBSERVATIONS IN P_1 FEMALE RATS DURING GESTATION

	NUMBER OF RATS WITH GIVEN SIGN			
GROUP:	II-0	IV-0	VI-0	VIII-0
DOSE (MG/KG/DAY):	0	10	100	1000
NUMBER IN GROUP:	20	20	20	20
NUMBER IN GESTATION[a]:	19	18	20	17
OBSERVATIONS[b]				
ALOPECIA	3	8	3	5
COLORED DISCHARGE RIGHT EYE(S)	1	0	0	0

a The number of animals in gestation includes only the animals that exhibit evidence of copulation.

b Clinical observations of "cageboard plugs," "sperm positive," "sperm negative," and "vaginal plug" are reported in the Appendix, "Individual Clinical Observations And Mortality Data In P_1 Female Rats During Gestation," and were used to calculate Reproductive Indices.

There were no statistically significant trends by Cochran-Armitage trend test; $p < 0.05$.

Company Sanitized. Does not contain TSCA CBI

TABLE 54

SUMMARY OF CLINICAL OBSERVATIONS IN P_1 FEMALE RATS DURING LACTATION

	NUMBER OF RATS WITH GIVEN SIGN			
GROUP:	II-0	IV-0	VI-0	VIII-0
DOSE (MG/KG/DAY):	0	10	100	1000
NUMBER IN GROUP:	20	20	20	20
NUMBER IN LACTATION:	19	20	19	19
OBSERVATIONS				
ALOPECIA	3	9	2	6
SORE	0	0	0	1
TOTAL NO. OF RATS WITH MASSES	0	0	0	1
SITE: MASS 0.5 cm SHOULDER	0	0	0	1

There were no statistically significant trends by Cochran-Armitage trend test; $p < 0.05$.

Company Sanitized. Does not contain TSCA CBI

TABLE 55

MEAN BODY WEIGHTS (grams) OF P_1 MALE RATS

Group:	I-0	III-0	V-0	VII-0
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 70	537.3	522.8	507.4	524.3
	49.1(20)	35.7(20)	44.3(20)	47.6(20)
Day 77	540.0	513.1	501.0	524.2
	53.1(20)	35.0(20)	40.0(20)	46.9(20)
Day 84	551.7	533.6	517.8	534.8
	53.6(20)	37.5(20)	40.4(20)	49.2(20)
Day 91	560.5	543.3	527.3	541.2
	57.0(20)	41.1(20)	41.6(20)	50.0(19)
Day 98	568.6	555.3	541.4	551.1
	56.6(20)	40.2(20)	44.2(20)	52.9(19)
Day 105	577.0	563.2	549.5	554.7
	58.6(20)	41.8(20)	42.2(20)	51.8(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.
Note: Day 70 = last weigh day of premating period, Day 77 = first weigh day of cohabitation period.

Company Sanitized. Does not contain TSCA CBI

TABLE 56

MEAN BODY WEIGHT GAINS (grams) OF P_1 MALE RATS

Group:	I-0	III-0	V-0	VII-0
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 70-77	2.8	-9.7	-6.3	-0.1
	9.9(20)	10.6(20)	21.1(20)	7.7(20)
Day 77-84	11.6	20.5	16.8	10.6
	6.8(20)	10.1(20)	10.8(20)	6.1(20)
Day 84-91	8.9	9.7	9.5	8.7
	6.5(20)	6.8(20)	9.2(20)	4.7(19)
Day 91-98	8.0	12.0	14.2	9.9
	8.1(20)	5.4(20)	5.6(20)	8.2(19)
Day 98-105	8.5	7.9	8.1	3.5
	6.4(20)	4.8(20)	5.8(20)	8.3(19)
Day 70-105	39.8	40.4	42.1	33.2
	18.1(20)	12.3(20)	15.8(20)	12.8(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.
Note: Day 70 = last weigh day of premating period, Day 77 = first weigh day of cohabitation period.

Company Sanitized. Does not contain TSCA CBI

TABLE 57

MEAN BODY WEIGHTS (grams) OF P_1 FEMALE RATS DURING GESTATION

Group:	II-0	IV-0	VI-0	VIII-0
Dosage(mg/kg/day):	0	10	100	1000
Gestation				
Day 0	297.2	298.3	299.8	301.2
	24.0(18)[a]	35.4(18)	28.7(19)	30.0(16)
Day 7	326.4	328.6	331.2	330.2
	27.0(18)	33.0(18)	32.2(19)	31.2(16)
Day 14	361.5	368.1	366.8	365.3
	26.7(18)	33.8(18)	36.0(19)	36.4(16)
Day 21	447.5	444.3	438.6	448.3
	33.2(18)	35.9(18)	37.9(19)	46.9(16)

Data summarized as: Mean
Standard Deviation (n)

a The number of animals in gestation includes only the animals that exhibit evidence of copulation.

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 58

MEAN BODY WEIGHT GAINS (grams) OF P_1 FEMALE RATS DURING GESTATION

Group:	II-0	IV-0	VI-0	VIII-0
Dosage(mg/kg/day):	0	10	100	1000
Gestation				
Day 0-7	29.2	30.4	31.4	28.9
	8.4(18)[a]	11.9(18)	8.6(19)	5.3(16)
Day 7-14	35.1	39.4	35.5	35.1
	12.7(18)	11.2(18)	9.1(19)	6.9(16)
Day 14-21	86.0	76.2	71.9	83.0
	13.5(18)	15.9(18)	22.1(19)	17.2(16)
Day 0-21	150.3	146.0	138.8	147.1
	16.3(18)	24.9(18)	25.4(19)	21.4(16)

Data summarized as: Mean
Standard Deviation (n)

a The number of animals in gestation includes only the animals that exhibit evidence of copulation.

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 59

MEAN BODY WEIGHTS (grams) OF P_1 FEMALE RATS DURING LACTATION

Group:	II-0	IV-0	VI-0	VIII-0
Dosage(mg/kg/day):	0	10	100	1000
Lactation				
Day 0	337.5	346.9	336.1	332.9
	27.6(19)	32.5(20)	30.8(18)[a]	37.2(19)
Day 7	350.9	358.4	356.9	354.5
	27.4(19)	30.6(20)	31.4(19)	33.7(19)
Day 14	362.8	368.9	366.0	367.5
	25.0(19)	26.5(19)	28.5(19)	31.0(19)
Day 21	336.5	347.1	348.2	347.1
	18.3(19)	24.6(19)	22.6(19)	29.2(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.
a N = 18; data inadvertently not recorded for Animal No. 665247 on lacatation day 0.

Company Sanitized. Does not contain TSCA CBI

TABLE 60

MEAN BODY WEIGHT GAINS (grams) OF P_1 FEMALE RATS DURING LACTATION

Group:	II-0	IV-0	VI-0	VIII-0
Dosage(mg/kg/day):	0	10	100	1000
Lactation				
Day 0-7	13.4	11.5	18.3	21.6#
	11.6(19)	18.2(20)	14.0(18)[a]	15.2(19)
Day 7-14	11.9	9.9	9.1	13.1
	9.0(19)	11.8(19)	10.8(19)	15.0(19)
Day 14-21	-26.3	-21.8	-17.8	-20.4
	18.1(19)	13.0(19)	13.1(19)	15.1(19)
Day 0-21	-1.1	2.6	11.0	14.3#
	23.3(19)	17.2(19)	18.7(18)[a]	21.4(19)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

a N = 18; data inadvertently not recorded for Animal No. 665247 on lacatation day 0.

Company Sanitized. Does not contain TSCA CBI

TABLE 61

MEAN DAILY FOOD CONSUMPTION (grams) OF P_1 FEMALE RATS DURING GESTATION

Group:	II-0	IV-0	VI-0	VIII-0
Dosage(mg/kg/day):	0	10	100	1000
Gestation				
Day 0-7	22.8	23.7	23.8	23.6
	2.0(18)[a]	3.0(18)	3.0(19)	2.3(16)
Day 7-14	26.0	27.1	26.6	25.9
	2.5(18)	3.0(18)	3.6(19)	2.7(16)
Day 14-21	26.3	26.4	26.1	26.7
	2.7(18)	2.4(18)	2.9(19)	2.1(16)
Day 0-21	25.1	25.7	25.5	25.4
	2.1(18)	2.3(18)	2.9(19)	2.2(16)

Data summarized as: Mean
Standard Deviation (n)

a The number of animals in gestation includes only the animals that exhibit evidence of copulation.

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 62

MEAN FOOD EFFICIENCY (grams weight gain/grams food consumed) OF P_1 FEMALE RATS DURING GESTATION

Group:	II-0	IV-0	VI-0	VIII-0
Dosage(mg/kg/day):	0	10	100	1000
Gestation				
Day 0-7	0.182	0.182	0.186	0.175
	0.047(18)[a]	0.064(18)	0.037(19)	0.029(16)
Day 7-14	0.190	0.207	0.190	0.192
	0.055(18)	0.053(18)	0.037(19)	0.024(16)
Day 14-21	0.470	0.415	0.398	0.442
	0.076(18)	0.094(18)	0.134(19)	0.077(16)
Day 0-21	0.286	0.271	0.261	0.275
	0.027(18)	0.044(18)	0.048(19)	0.025(16)

Data summarized as: Mean
Standard Deviation (n)

a The number of animals in gestation includes only the animals that exhibit evidence of copulation.

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 63

SUMMARY OF REPRODUCTIVE INDICES: P_1 GENERATION

MATERNAL GROUP:	II-0	IV-0	VI-0	VIII-0
DOSE (mg/kg/day):	0	10	100	1000
MATING INDEX (%)	100	100	100	100
(No. copulated/cohoused)	(20/20)	(20/20)	(20/20)	(20/20)
FERTILITY INDEX (%)	95	100	95	95
(No. pregnant/copulated)	(19/20)	(20/20)	(19/20)	(19/20)
GESTATION LENGTH (days)	22.2	22.7	22.6	22.3
(No. in group)	(18)	(18)	(19)	(16)
NUMBER OF IMPLANTATION SITES				
per pregnant female	14.7	14.5	14.0	15.4
Standard Deviation (No. in group)	2.1(19)	3.3(20)	3.9(19)	2.4(19)
IMPLANTATION EFFICIENCY (%)[a]	90.5	80.8	89.5	92.6
Standard Deviation(No. in group)	9.3(19)	19.1(20)	10.3(19)	11.8(19)

a Number of pups born/number of implantation sites X 100.

There were no statistically significant trends in mating or fertility indices by Cochran-Armitage test; $p < 0.05$.

There were no statistically significant trends in gestation length or number of implantation sites by Jonckheere-Terpstra test; $p < 0.05$.

Company Sanitized. Does not contain TSCA CBI

TABLE 64

SUMMARY OF SPERM PARAMETERS IN P_1 MALE RATS

Group	I-0	III-0	V-0	VII-0
Dose (mg/kg/day)	0	10	100	1000
MOTILITY				
Percent Motile	86	89	91	90
Standard Deviation	11(10)	9(10)	8(10)	5(10)
MORPHOLOGY				
Percent Normal	99.4	99.2	99.1	99.0
Standard Deviation	0.7(10)	1.3(10)	0.8(10)	0.9(10)
EPIDIDYMAL SPERM (Millions)				
Per Cauda	264.6	254.4	258.4	252.2
Standard Deviation	14.9(10)	6.5(10)	10.5(10)	9.0(10)
Per gram Cauda	985.8	961.2	1101.5	1065.2
Standard Deviation	125.8(10)	102.2(10)	134.2(10)	141.8(10)
TESTICULAR SPERMATIDS (Millions)				
Per Testis	136.3	134.2	132.2	131.9
Standard Deviation	4.4(10)	4.2(10)	5.2(10)	7.6(10)
Per gram Testis	84.5	84.0	82.4	80.2
Standard Deviation	9.5(10)	4.5(10)	9.0(10)	15.7(10)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 65

MEAN ESTROUS CYCLE PARAMETERS AND PRECOITAL INTERVAL IN P_1 FEMALE RATS

Group	Dose (mg/gk/day)	N	Percent of Days in Estrus	Percent of Days in Diestrus	Percent of Days in Proestrus	Mean Cycle Length (days)	Mean Precoital Interval (days)
II-0	0	20	34%	56%	10%	4.1(0.3)[a]	3.0(3.4)
IV-0	10	20	30%	62%	8%	4.1(0.3)	2.9(1.7)
VI-0	100	20	31%	60%	8%	4.2(0.4)	3.0(2.5)
VIII-0	1000	20	26%	62%	12%	4.3(0.4)	2.8(1.5)

a Standard deviation is presented in parentheses.

There were no statistically significant trends in estrous cycle length or precoital interval by Jonckheere-Terpstra test ($p < 0.05$).

Company Sanitized. Does not contain TSCA CBI

TABLE 66

MEAN PUP NUMBERS AND SURVIVAL: F_1 GENERATION

MATERNAL GROUP:	II-0	IV-0	VI-0	VIII-0
DOSE (mg/kg/day):	0	10	100	1000
N:	19	20[a]	19	19
MEAN NUMBER OF PUPS/LITTER				
Born	13.4	11.8	12.5	14.3
Born Alive	13.4	11.4	12.4	14.2
Day 4 Preculling	13.3	11.9	12.4	14.1
Day 4 Postculling	7.9	7.7	7.6	7.9
Day 7	7.8	7.7	7.6	7.9
Day 14	7.8	7.7	7.6	7.9
Day 21	7.8	7.7	7.6	7.9
MEAN NUMBER OF MALE PUPS/LITTER				
Born	6.6	6.1	6.7	7.6
Born Alive	6.6	6.2[b]	6.7	7.5
Day 4 Preculling	6.5	6.0	6.7	7.4
Day 4 Postculling	3.9	3.8	4.0	4.0
Day 7	3.9	3.8	4.0	4.0
Day 14	3.9	3.8	4.0	4.0
Day 21	3.9	3.8	4.0	4.0
MEAN NUMBER OF FEMALE PUPS/LITTER				
Born	6.8	6.0	5.7	6.7
Born Alive	6.8	6.0[b]	5.7	6.7
Day 4 Preculling	6.8	5.9	5.7	6.7
Day 4 Postculling	4.0	3.9	3.6	3.9
Day 7	3.9	3.9	3.6	3.9
Day 14	3.9	3.9	3.6	3.9
Day 21	3.9	3.9	3.6	3.9
SURVIVAL (%)				
Sex Ratio (males)	0.49	0.53	0.54	0.53
Gestation Index[c]	100.0	95.0	100.0	100.0
Mean % Born Alive	100.0	93.8	99.4	99.0
0-4 Day Viability	99.6	99.6	100.0	99.3
Lactation Index[d]	99.3	100.0	99.3	100.0
Litter Survival[e]	100.0	100.0	100.0	100.0

a N = 19 for Day 4 Preculling to Day 21, 0-4 Day Viability, Lactation Index, and Litter Survival.
b N = 18 due to a missexed pup.
c Percent litters delivered having at least one live pup.
d Mean percent survival from Day 4 Postculling to Day 21.
e Percent litters born with at least one pup alive on Day 21.

There were no statistically significant trends in number of pups, sex ratio, mean percent born alive, 0-4 day viability, or lactation index by Jonckheere-Terpstra test; $p < 0.05$.

There were no statistically significant trends in gestation index and litter survival by Cochran-Armitage test; $p < 0.05$.

Statistics were performed on combined pups per litter only. Male and female data are presented for information only.

Company Sanitized. Does not contain TSCA CBI

TABLE 67

SUMMARY OF PUP CLINICAL OBSERVATIONS: F_1 GENERATION

MATERNAL GROUP:	II-0	IV-0	VI-0	VIII-0
DOSE (mg/kg/day):	0	10	100	1000
TOTAL NUMBER OF LITTERS:	19	19	19	19
OBSERVATIONS				
SMALL WHOLE BODY	0	0	1 (1)	1 (1)
TOTAL NUMBER OF SIGNS	0	0	1	1
NUMBER OF LITTERS AFFECTED	0	0	1	1

Numbers outside the parentheses are the number of pups affected; the numbers in parentheses are the number of litters affected.

There were no statistically significant trends by Cochran-Armitage test; $p < 0.05$.

Company Sanitized. Does not contain TSCA CBI

TABLE 68

MEAN PUP WEIGHTS: F_1 GENERATION

MATERNAL GROUP:	II-0	IV-0	VI-0	VIII-0
DOSE (mg/kg/day):	0	10	100	1000
N:	19	19	19	19
	MEAN PUP WEIGHTS (grams)			
Day 0	6.8 (0.7)	7.2 (0.7)	7.2 (0.8)	6.6 (0.6)
Day 4 Preculling	11.2 (1.5)	12.2 (1.7)	12.2 (2.0)	10.9 (1.7)
Day 4 Postculling	11.2 (1.6)	12.3 (1.8)	12.2 (2.1)	10.9 (1.7)
Day 7	18.5 (2.4)	19.3 (2.1)	19.5 (2.7)	17.6 (2.4)
Day 14	37.9 (3.8)	38.4 (3.0)	39.2 (4.0)	37.2 (3.6)
Day 21	60.4 (6.5)	62.7 (4.4)	63.6 (6.0)	60.7 (5.7)
	MEAN MALE PUP WEIGHTS (grams)			
Day 0	7.1 (0.7)	7.4 (0.6)	7.4 (0.8)	6.8 (0.7)
Day 4 Preculling	11.7 (1.6)	12.5 (1.7)	12.4 (2.0)	11.2 (1.6)
Day 4 Postculling	11.6 (1.7)	12.5 (1.7)	12.5 (2.0)	11.2 (1.7)
Day 7	19.0 (2.5)	19.8 (2.0)	19.9 (2.5)	18.2 (2.4)
Day 14	38.6 (4.0)	39.0 (3.1)	39.9 (3.8)	38.0 (3.6)
Day 21	61.9 (6.9)	64.2 (4.9)	65.2 (5.6)	62.7 (6.2)
	MEAN FEMALE PUP WEIGHTS (grams)			
Day 0	6.6 (0.6)	7.0 (0.7)	7.0 (0.9)	6.4 (0.7)
Day 4 Preculling	10.9 (1.4)	11.9 (1.8)	11.8 (2.1)	10.5 (1.7)
Day 4 Postculling	10.9 (1.5)	12.0 (1.8)	11.9 (2.2)	10.5 (1.8)
Day 7	18.0 (2.3)	18.9 (2.2)	18.8 (2.9)	17.1 (2.4)
Day 14	37.2 (3.8)	37.7 (2.9)	38.4 (4.2)	36.4 (3.6)
Day 21	58.9 (6.5)	61.0 (4.0)	61.8 (6.0)	58.7 (5.3)

Data summarized as: Mean (Standard Deviation)

There were no statistically significant trends by linear contrast of least square means; $p < 0.05$.

Note: Statistical analyses were conducted on the combined pup weights. Male and female data are presented for information only.

Company Sanitized. Does not contain TSCA CBI

TABLE 69

SUMMARY OF CLINICAL OBSERVATIONS IN F_1 MALE RATS

	NUMBER OF RATS WITH GIVEN SIGN			
GROUP:	I-1	III-1	V-1	VII-1
DOSE (mg/kg/day):	0	10	100	1000
NUMBER IN GROUP:	19	19	19	19
OBSERVATIONS				
ALOPECIA	2	1	2	0
COLORED DISCHARGE NOSE	0	1	0	0
PREPUTIAL SEPARATION COMPLETE	19	19	19	19
SORE	0	1	0	0

There were no statistically significant trends by Cochran-Armitage trend test; $p < 0.05$.

Company Sanitized. Does not contain TSCA CBI

TABLE 70

SUMMARY OF CLINICAL OBSERVATIONS IN F_1 FEMALE RATS

	NUMBER OF RATS WITH GIVEN SIGN			
GROUP:	II-1	IV-1	VI-1	VIII-1
DOSE (%):	0	10	100	1000
NUMBER IN GROUP:	19	19	19	19
OBSERVATIONS				
ALOPECIA	0	1	0	0
ENOPHTHALMUS	0	0	1	0
VAGINAL PATENCY COMPLETE	19	19	19	19

There were no statistically significant trends by Cochran-Armitage trend test; $p < 0.05$.

Company Sanitized. Does not contain TSCA CBI

TABLE 71

MEAN BODY WEIGHTS (grams) OF F_1 MALE RATS

Group:	I-1	III-1	V-1	VII-1
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 1	60.6	62.3	65.6	62.4
	7.9(19)	6.0(19)	6.8(19)	5.5(19)
Day 8	104.8	108.0	114.1	107.4
	12.4(19)	10.2(19)	12.0(19)	10.2(19)
Day 15	170.0	174.1	180.9	170.3
	18.6(19)	15.3(19)	19.7(19)	17.3(19)
Day 22	236.9	241.6	248.6	234.0
	24.2(19)	17.7(19)	26.0(19)	21.6(19)
Day 36	362.7	361.0	372.6	356.7
	36.0(19)	32.0(19)	35.8(18)[a]	32.9(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

a N = 18; data inadvertently not recorded for Animal No. 670403 on test day 36.

Company Sanitized. Does not contain TSCA CBI

TABLE 72

MEAN BODY WEIGHTS GAINS (grams) OF F_1 MALE RATS

Group:	I-1	III-1	V-1	VII-1
Dosage (mg/kg/day):	0	10	100	1000
Test				
Day 1-8	44.3 5.9(19)	45.7 5.4(19)	48.5 5.9(19)	45.0 6.2(19)
Day 8-15	65.1 7.6(19)	66.2 6.1(19)	66.8 9.1(19)	62.9 10.0(19)
Day 15-22	67.0 7.8(19)	67.5 5.9(19)	67.7 8.4(19)	63.7 8.0(19)
Day 22-36	125.8 15.6(19)	119.4 22.1(19)	122.3 16.0(18)[a]	122.7 15.5(19)
Day 1-36	302.2 32.0(19)	298.8 29.6(19)	306.7 30.6(18)[a]	294.3 30.2(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

a N = 18; data inadvertently not recorded for Animal No. 670403 on test day 36.

Company Sanitized. Does not contain TSCA CBI

TABLE 73

MEAN BODY WEIGHTS (grams) OF F_1 FEMALE RATS

Group:	II-1	IV-1	VI-1	VIII-1
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 1	58.9 6.4(19)	60.3 4.6(19)	60.9 6.8(19)	59.0 4.9(19)
Day 8	97.6 10.0(19)	100.3 9.5(19)	100.4 12.4(19)	99.5 11.4(19)
Day 15	144.1 14.4(19)	143.7 14.9(19)	144.4 14.5(19)	145.5 16.4(19)
Day 22	177.7 17.5(19)	178.3 20.9(19)	178.4 17.3(19)	177.9 19.9(19)
Day 36	228.3 26.1(19)	225.0 30.0(19)	229.1 18.4(18)	223.6 28.1(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 74

MEAN BODY WEIGHTS GAINS (grams) OF F_1 FEMALE RATS

Group:	II-1	IV-1	VI-1	VIII-1
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 1-8	38.8 4.6(19)	40.0 5.7(19)	39.5 6.8(19)	40.5 7.8(19)
Day 8-15	46.5 6.6(19)	43.4 6.9(19)	44.0 4.7(19)	46.0 6.3(19)
Day 15-22	33.5 7.9(19)	34.6 9.4(19)	33.9 7.4(19)	32.4 7.6(19)
Day 22-36	50.7 11.5(19)	46.8 12.7(19)	48.9 6.1(18)	45.8 12.2(19)
Day 1-36	169.5 21.7(19)	164.7 27.7(19)	167.7 14.4(18)	164.7 25.8(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 75

MEAN DAILY FOOD CONSUMPTION (grams) OF F_1 MALE RATS

Group:	I-1	III-1	V-1	VII-1
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 1-8	12.0 1.3(19)	12.8 1.5(19)	12.9 1.3(19)	12.3 1.2(19)
Day 8-15	19.3 2.2(19)	19.9 1.9(19)	20.4 2.8(19)	19.2 2.3(19)
Day 15-22	25.1 3.0(19)	25.5 2.3(19)	25.9 3.6(19)	24.3 2.6(19)
Day 22-36	29.0 3.6(19)	29.4 2.6(19)	29.7 5.0(19)	28.3 2.9(19)
Day 1-36	22.9 2.6(19)	23.4 1.9(19)	23.7 2.8(19)	22.5 2.1(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 76

MEAN DAILY FOOD EFFICIENCY (grams weight gain/grams food consumed) OF F_1 MALE RATS

Group:	I-1	III-1	V-1	VII-1
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 1-8	0.527	0.511	0.535	0.521
	0.033(19)	0.034(19)	0.024(19)	0.032(19)
Day 8-15	0.483	0.475	0.469	0.467
	0.029(19)	0.025(19)	0.020(19)	0.040(19)
Day 15-22	0.383	0.379	0.375	0.374
	0.030(19)	0.026(19)	0.031(19)	0.036(19)
Day 22-36	0.310	0.289	0.303	0.310
	0.018(19)	0.043(19)	0.028(18)a	0.027(19)
Day 1-36	0.378	0.365	0.374	0.374
	0.016(19)	0.019(19)	0.019(18)a	0.016(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

a N = 18; body weight data inadvertently not recorded for Animal No. 670403 on test day 36.

Company Sanitized. Does not contain TSCA CBI

TABLE 77

MEAN DAILY FOOD CONSUMPTION (grams) OF F_1 FEMALE RATS

Group:	II-1	IV-1	VI-1	VIII-1
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 1-8	11.3 0.9(19)	11.8 1.4(19)	11.5 1.6(19)	11.9 1.4(19)
Day 8-15	16.4 1.6(19)	16.9 2.1(19)	16.4 2.0(19)	17.1 2.2(19)
Day 15-22	18.8 1.7(19)	18.8 2.9(19)	18.6 2.0(19)	18.6 1.9(19)
Day 22-36	19.2 2.2(19)	19.0 3.0(19)	19.5 3.4(19)	19.1 2.1(19)
Day 1-36	17.0 1.6(19)	17.1 2.3(19)	17.1 1.5(19)	17.2 1.8(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 78

MEAN FOOD EFFICIENCY (grams weight gain/grams food consumed) OF F_1 FEMALE RATS

Group:	II-1	IV-1	VI-1	VIII-1
Dosage(mg/kg/day):	0	10	100	1000
Test				
Day 1-8	0.490 0.041(19)	0.483 0.036(19)	0.489 0.039(19)	0.482 0.046(19)
Day 8-15	0.406 0.042(19)	0.366 0.031(19)	0.386 0.042(19)	0.384 0.030(19)
Day 15-22	0.255 0.054(19)	0.261 0.042(19)	0.261 0.051(19)	0.247 0.047(19)
Day 22-36	0.187 0.032(19)	0.174 0.036(19)	0.186 0.023(18)	0.169 0.035(19)
Day 1-36	0.285 0.024(19)	0.274 0.020(19)	0.283 0.016(18)	0.273 0.023(19)

Data summarized as: Mean
Standard Deviation (n)

There were no statistically significant trends at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 79

SUMMARY OF DEVELOPMENTAL LANDMARKS IN F_1 RATS

PREPUTIAL SEPARATION - F_1 MALE RATS

	Number of Rats with Given Sign			
GROUP:	I-1	III-1	V-1	VII-1
DOSE (mg/kg/day):	0	10	100	1000
N:	19	19	19	19
OBSERVATIONS				
AGE (Days)[a]	41.5	41.4	41.5	42.1
	1.7	1.3	1.6	1.5

VAGINAL PATENCY - F_1 FEMALE RATS

	Number of Rats with Given Sign			
GROUP:	II-1	IV-1	VI-1	VIII-1
DOSE (mg/kg/day):	0	10	100	1000
N:	19	19	19	19
OBSERVATIONS				
AGE (Days)[a]	31.3	31.1	31.6	31.7
	1.6	1.4	1.5	1.5

Data summarized as: Mean
Standard Deviation

a Age was calculated as follows using data presented in the Appendix, "Individual Clinical Observations, Developmental Landmarks, and Mortality Data for F_1 Male and Female Rats:"
Test day + 20 days = Age (days).

There were no statistically significant trends by Jonckheere-Terpstra test ($p < 0.05$).

Company Sanitized. Does not contain TSCA CBI

TABLE 80

MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS - F_1 ADULT

MEAN FINAL BODY AND ABSOLUTE ORGAN WEIGHTS (grams)

Group: Dosage(mg/kg)	I-1 0	III-1 10	V-1 100	VII-1 1000
Final Body Weight	393.4 39.9(19)	394.1 32.4(19)	397.1 38.9(19)	386.2 36.3(19)
Liver	18.341 2.949(19)	18.194 1.932(19)	17.880 2.272(19)	17.782 2.393(19)
Thyroid Gland	0.021 0.005(19)	0.018 0.004(19)	0.021 0.005(19)	0.021 0.006(18)
Testes	3.089 0.305(19)	3.190 0.263(19)	3.357 0.406(19)	3.200 0.166(19)
Epididymides	0.724 0.062(19)	0.741 0.075(19)	0.791 0.097(19)	0.733 0.065(19)
Prostate	0.449 0.089(19)	0.475 0.060(19)	0.476 0.112(19)	0.434 0.074(19)
Seminal Vesicles	1.298 0.153(19)	1.348 0.162(19)	1.350 0.187(19)	1.249 0.241(19)
Brain	1.956 0.079(19)	1.976 0.117(19)	1.979 0.093(19)	1.916 0.074(19)

Company Sanitized. Does not contain TSCA CBI

TABLE 80 (Continued)

MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS - F_1 ADULT

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group:	I-1	III-1	V-1	VII-1
Dosage(mg/kg)	0	10	100	1000
Liver/ Final Body * 100	4.644	4.616	4.499	4.592
	0.467(19)	0.292(19)	0.322(19)	0.303(19)
Thyroid Gland/ Final Body * 100	0.005	0.005	0.005	0.005
	0.001(19)	0.001(19)	0.001(19)	0.002(18)
Testes/ Final Body * 100	0.792	0.814	0.849	0.834
	0.099(19)	0.090(19)	0.097(19)	0.068(19)
Epididymides/ Final Body * 100	0.186	0.188	0.200	0.191
	0.025(19)	0.016(19)	0.020(19)	0.023(19)
Prostate/ Final Body * 100	0.114	0.122	0.120	0.113
	0.021(19)	0.020(19)	0.025(19)	0.020(19)
Seminal Vesicles/ Final Body * 100	0.333	0.345	0.341	0.324
	0.046(19)	0.057(19)	0.040(19)	0.057(19)
Brain/ Final Body * 100	0.502	0.503	0.501	0.500
	0.055(19)	0.029(19)	0.037(19)	0.047(19)

Company Sanitized. Does not contain TSCA CBI

TABLE 80 (Continued)

MEAN FINAL BODY AND ORGAN WEIGHTS FROM MALE RATS - F_1 ADULT

MEAN RELATIVE ORGAN WEIGHTS (% organ to brain weight ratio)

Group: Dosage(mg/kg)	I-1 0	III-1 10	V-1 100	VII-1 1000
Liver/ Brain * 100	939.300 161.625(19)	920.489 77.991(19)	903.253 102.214(19)	928.167 121.927(19)
Thyroid Gland/ Brain * 100	1.083 0.288(19)	0.939 0.219(19)	1.067 0.225(19)	1.071 0.320(18)
Testes/ Brain * 100	158.081 16.060(19)	161.860 14.729(19)	169.804 19.879(19)	167.124# 7.893(19)
Epididymides/ Brain * 100	37.065 3.615(19)	37.520 3.111(19)	39.960 4.416(19)	38.276 3.232(19)
Prostate/ Brain * 100	23.006 4.748(19)	24.152 3.397(19)	24.001 5.339(19)	22.728 4.118(19)
Seminal Vesicles/ Brain * 100	66.378 7.352(19)	68.409 8.556(19)	68.283 9.473(19)	65.203 12.520(19)

Data summarized as: Mean
Standard Deviation (n)

\# Statistically significant difference from control at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 81

MEAN FINAL BODY AND ORGAN WEIGHTS FROM FEMALE RATS - F_1 ADULT

MEAN FINAL BODY AND ABSOLUTE ORGAN WEIGHTS (grams)

Group: Dosage(mg/kg)	II-1 0	IV-1 10	VI-1 100	VIII-1 1000
Final Body Weight	241.8 23.2(19)	239.6 31.4(19)	236.4 20.4(19)	235.6 27.8(19)
Liver	10.735 0.990(19)	10.406 1.804(19)	10.032 1.062(19)	9.859# 1.048(19)
Thyroid Gland	0.016 0.002(18)	0.018 0.003(19)	0.016 0.003(19)	0.016 0.004(19)
Uterus	0.474 0.160(19)	0.488 0.156(19)	0.487 0.125(19)	0.516 0.153(19)
Brain	1.809 0.098(19)	1.813 0.088(19)	1.803 0.077(19)	1.790 0.080(19)

Company Sanitized. Does not contain TSCA CBI

TABLE 81 (Continued)

MEAN FINAL BODY AND ORGAN WEIGHTS FROM FEMALE RATS - F_1 ADULT

MEAN RELATIVE ORGAN WEIGHTS (% of body weight)

Group: Dosage(mg/kg)	II-1 0	IV-1 10	VI-1 100	VIII-1 1000
Liver/ Final Body * 100	4.449 0.267(19)	4.324 0.304(19)	4.246# 0.302(19)	4.199# 0.283(19)
Thyroid Gland/ Final Body * 100	0.007 0.001(18)	0.008 0.002(19)	0.007 0.002(19)	0.007 0.002(19)
Uterus/ Final Body * 100	0.198 0.072(19)	0.211 0.088(19)	0.207 0.054(19)	0.218 0.053(19)
Brain/ Final Body * 100	0.752 0.050(19)	0.766 0.081(19)	0.767 0.055(19)	0.768 0.076(19)

Company Sanitized. Does not contain TSCA CBI

TABLE 81 (Continued)

MEAN FINAL BODY AND ORGAN WEIGHTS FROM FEMALE RATS - F_1 ADULT

MEAN RELATIVE ORGAN WEIGHTS (% organ to brain weights ratio)

Group:	II-1	IV-1	VI-1	VIII-1
Dosage(mg/kg)	0	10	100	1000
Liver/ Brain * 100	593.399	573.029	556.621	550.923#
	42.559(19)	91.618(19)	56.505(19)	55.195(19)
Thyroid Gland/ Brain * 100	0.868	1.018	0.861	0.898
	0.141(18)	0.199(19)	0.177(19)	0.204(19)
Uterus/ Brain * 100	26.323	27.100	27.130	28.827
	9.210(19)	9.514(19)	7.497(19)	8.551(19)

Data summarized as: Mean
Standard Deviation (n)

Statistically significant difference from control at $p < 0.05$ by Jonckheere-Terpstra trend test.

Company Sanitized. Does not contain TSCA CBI

TABLE 82

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS - P_1 ADULTS

SITE/LESION:	GROUP DESIGNATION:	I-0	III-0	V-0	VII-0
	DOSE (mg/kg):	0	10	100	1000
	NUMBER IN GROUP:	20	20	20	20
SKIN					
ULCER/EROSION		0	0	0	1
WHOLE BODY					
AUTOLYSIS		0	0	0	1

NOTE:
- INCIDENCES REFLECT THE NUMBER OF ANIMALS WITH A GIVEN LESION.

Company Sanitized. Does not contain TSCA CBI

TABLE 83

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS - P_1 ADULTS

SITE/LESION:	GROUP DESIGNATION:	II-0	IV-0	VI-0	VIII-0
	DOSE (mg/kg):	0	10	100	1000
	NUMBER IN GROUP:	20	20	20	20
LIVER					
LARGE					
DISCOLORATION		0	1	0	0
		1	0	0	0
KIDNEYS					
DISCOLORATION		0	1	0	0
SPLEEN					
LARGE		0	1	0	0
THYMUS					
EDEMA		0	1	0	0
VAGINA					
FLUID		0	1	0	0
SKIN					
ALOPECIA		0	1	1	0

NOTE:
- INCIDENCES REFLECT THE NUMBER OF ANIMALS WITH A GIVEN LESION.

Company Sanitized. Does not contain TSCA CBI

TABLE 84

INCIDENCES OF GROSS OBSERVATIONS IN MALE RATS - F_1 ADULTS

SITE/LESION:	GROUP DESIGNATION:	I-1	III-1	V-1	VII-1
	DOSE (mg/kg):	0	10	100	1000
	NUMBER IN GROUP:	25	19	24	23
MESENTERY					
DISCOLORATION		0	0	1	0
KIDNEYS					
DILATATION		0	0	0	2

NOTE:
- INCIDENCES REFLECT THE NUMBER OF ANIMALS WITH A GIVEN LESION.

Company Sanitized. Does not contain TSCA CBI

TABLE 85

INCIDENCES OF GROSS OBSERVATIONS IN FEMALE RATS - F_1 ADULTS

SITE/LESION:	GROUP DESIGNATION:	II-1	IV-1	VI-1	VIII-1
	DOSE (mg/kg):	0	10	100	1000
	NUMBER IN GROUP:	25	24	24	24
NO ABNORMALITIES DETECTED					

NOTE:
- INCIDENCES REFLECT THE NUMBER OF ANIMALS WITH A GIVEN LESION.

Company Sanitized. Does not contain TSCA CBI

TABLE 86

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN MALE RATS - P_1 ADULTS

TISSUE/LESION	LESION GRADES (P,1,2,3,4)	GROUP DESIGNATION: DOSE (mg/kg): NUMBER IN GROUP:	I-0 0 20	III-0 10 20	V-0 100 20	VII-0 1000 20
REPRODUCTIVE SYSTEM						
TESTES						
ONE OF PAIR NOT PRESENT			1	0	1	2
			-	-	1 (1,-,-,-,-)	1 (1,-,-,-,-)
EPIDIDYMIDES			1	0	1	2
PROSTATE						
AGGREGATES, LYMPHOID			1	0	1	2
			1 (-,1,-,-,-)	-	1 (-,1,-,-,-)	1 (-,-,1,-,-)
SEMINAL VESICLES			1	0	1	2
COAGULATING GLANDS			1	0	0	1
ENDOCRINE SYSTEM						
PITUITARY GLAND			0	0	0	1
THYROID GLAND			0	0	0	0
OTHER						
CAUSE OF DEATH						
SACRIFICED BY DESIGN			1	0	1	2
			1 (1,-,-,-,-)	-	1 (1,-,-,-,-)	1 (1,-,-,-,-)
UNDETERMINED			-	-	-	1 (1,-,-,-,-)

NOTES:
- THE NUMBER OF ORGANS EXAMINED FOR EACH GROUP IS UNDERLINED.
- LESION GRADES: P = PRESENT; 1 = MINIMAL; 2 = MILD; 3 = MODERATE; 4 = SEVERE.
- LESION GRADES CORRESPOND BY POSITION WITH THE NUMBERS IN PARENTHESES, WHICH INDICATE HOW OFTEN EACH GRADE WAS OBSERVED. FOR EXAMPLE: (-,1,2,-,-) MEANS NO LESIONS WERE GRADED "PRESENT" (NON-GRADED LESIONS), 1 LESION WAS GRADED "MINIMAL", 2 LESIONS WERE GRADED "MILD", NO LESIONS WERE GRADED "MODERATE" AND NO LESIONS WERE GRADED "SEVERE".

Company Sanitized. Does not contain TSCA CBI

TABLE 87

INCIDENCES AND LESION GRADES OF MICROSCOPIC OBSERVATIONS IN FEMALE RATS - P1 ADULTS

TISSUE/LESION	LESION GRADES (P,1,2,3,4)	GROUP DESIGNATION: DOSE (mg/kg): NUMBER IN GROUP:	II-0 0 20	IV-0 10 20	VI-0 100 20	VIII-0 1000 20
REPRODUCTIVE SYSTEM						
OVARIES			1	1	1	1
UTERUS			1	1	1	1
VAGINA			1	1	1	1
ESTRUS STAGE: ESTRUS			-	-	1 (1,-,-,-,-)	1 (1,-,-,-,-)
ESTRUS STAGE: METESTRUS			-	-	-	-
ESTRUS STAGE: PROESTRUS			1 (1,-,-,-,-)	1 (1,-,-,-,-)	-	-
ENDOCRINE SYSTEM						
PITUITARY GLAND			0	1	0	0
CYST			-	1 (-,1,-,-,-)	-	-
THYROID GLAND			0	1	0	0
OTHER						
CAUSE OF DEATH			1	1	1	1
SACRIFICED BY DESIGN			1 (1,-,-,-,-)	-	1 (1,-,-,-,-)	1 (1,-,-,-,-)
UNDETERMINED			-	1 (1,-,-,-,-)	-	-

NOTES:

- THE NUMBER OF ORGANS EXAMINED FOR EACH GROUP IS UNDERLINED.
- LESION GRADES: P = PRESENT; 1 = MINIMAL; 2 = MILD; 3 = MODERATE; 4 = SEVERE.
- LESION GRADES CORRESPOND BY POSITION WITH THE NUMBERS IN PARENTHESES, WHICH INDICATE HOW OFTEN EACH GRADE WAS OBSERVED. FOR EXAMPLE: (-,1,2,-,-) MEANS NO LESIONS WERE GRADED "PRESENT" (NON-GRADED LESIONS), 1 LESION WAS GRADED "MINIMAL", 2 LESIONS WERE GRADED "MILD", NO LESIONS WERE GRADED "MODERATE" AND NO LESIONS WERE GRADED "SEVERE".

Company Sanitized. Does not contain TSCA CBI

TABLE 88

INCIDENCES OF GROSS OBSERVATIONS IN GENERATION F_1 MALE WEANLINGS

SITE/LESION:	DAM GROUP DESIGNATION:	II-0	IV-0	VI-0	VIII-0
	DOSE (mg/kg):	0	10	100	1000
	NUMBER WEANLINGS/LITTERS:	55/19	53/19	52/17	57/19
KIDNEYS					
DILATATION		0 (0)	0 (0)	1 (1)	0 (0)
TOTAL LITTERS AFFECTED		0	0	1	0
TOTAL WEANLINGS AFFECTED		0	0	1	0

For each group: The count of weanlings only includes those which underwent pathological examination.
The count of litters only includes those in which weanlings underwent pathological examination.

For each site/lesion: Numbers outside the parentheses are the number of weanlings affected.
Numbers in parentheses are the number of litters affected.

Company Sanitized. Does not contain TSCA CBI

TABLE 89

INCIDENCES OF GROSS OBSERVATIONS IN GENERATION F_1 FEMALE WEANLINGS

SITE/LESION:	DAM GROUP DESIGNATION:	II-0	IV-0	VI-0	VIII-0
	DOSE (mg/kg):	0	10	100	1000
	NUMBER WEANLINGS/LITTERS:	56/19	55/18	49/17	55/19
KIDNEYS					
DILATATION		1 (1)	0 (0)	0 (0)	1 (1)
WHOLE BODY					
SMALL		1 (1)	0 (0)	0 (0)	0 (0)
TOTAL LITTERS AFFECTED		2	0	0	1
TOTAL WEANLINGS AFFECTED		2	0	0	1

For each group: The count of weanlings only includes those which underwent pathological examination.
The count of litters only includes those in which weanlings underwent pathological examination.

For each site/lesion: Numbers outside the parentheses are the number of weanlings affected.
Numbers in parentheses are the number of litters affected.

Company Sanitized. Does not contain TSCA CBI

TABLE 90

INCIDENCES OF GROSS OBSERVATIONS IN GENERATION F_1 MALE PUPS

DAM GROUP DESIGNATION:	II-0	IV-0	VI-0	VIII-0
DOSE (mg/kg):	0	10	100	1000
SITE/LESION: NUMBER PUPS/LITTERS:	0/0	6/2	1/1	2/2
STOMACH				
NO MILK SPOT	0 (0)	3 (2)	0 (0)	1 (1)
LUNGS				
NOT EXPANDED	0 (0)	2 (1)	0 (0)	1 (1)
WHOLE BODY				
SMALL	0 (0)	0 (0)	0 (0)	1 (1)
AUTOLYSIS	0 (0)	2 (1)	0 (0)	1 (1)
TOTAL LITTERS AFFECTED	0	2	0	2
TOTAL PUPS AFFECTED	0	5	0	2

For each group: The count of pups only includes those which underwent pathological examination.
The count of litters only includes those in which pups underwent pathological examination.

For each site/lesion: Numbers outside the parentheses are the number of pups affected.
Numbers in parentheses are the number of litters affected.

Company Sanitized. Does not contain TSCA CBI

TABLE 91

INCIDENCES OF GROSS OBSERVATIONS IN GENERATION F_1 FEMALE PUPS

SITE/LESION:	DAM GROUP DESIGNATION: II-0 DOSE (mg/kg): 0 NUMBER PUPS/LITTERS: 0/0	IV-0 10 1/1	VI-0 100 2/1	VIII-0 1000 1/1
STOMACH				
NO MILK SPOT	0 (0)	1 (1)	1 (1)	0 (0)
LUNGS				
NOT EXPANDED	0 (0)	1 (1)	1 (1)	0 (0)
SKULL				
HEMORRHAGE	0 (0)	0 (0)	1 (1)	0 (0)
TOTAL LITTERS AFFECTED	0	1	1	0
TOTAL PUPS AFFECTED	0	1	2	0

For each group: The count of pups only includes those which underwent pathological examination.
The count of litters only includes those in which pups underwent pathological examination.

For each site/lesion: Numbers outside the parentheses are the number of pups affected.
Numbers in parentheses are the number of litters affected.

Company Sanitized. Does not contain TSCA CBI

TABLE 92

INCIDENCES OF GROSS OBSERVATIONS IN GENERATION F_1 UNSEXABLE PUPS

SITE/LESION:	DAM GROUP DESIGNATION:	II-0	IV-0	VI-0	VIII-0
	DOSE (mg/kg):	0	10	100	1000
	NUMBER PUPS/LITTERS:	0/0	0/0	0/0	0/0
NO UNSEXED PUPS					
TOTAL LITTERS AFFECTED		0	0	0	0
TOTAL PUPS AFFECTED		0	0	0	0

For each group: The count of pups only includes those which underwent pathological examination.
The count of litters only includes those in which pups underwent pathological examination.

For each site/lesion: Numbers outside the parentheses are the number of pups affected.
Numbers in parentheses are the number of litters affected.

Company Sanitized. Does not contain TSCA CBI

FIGURES

Company Sanitized. Does not contain TSCA CBI

FIGURES

EXPLANATORY NOTES

Critical Dates

Day 72 Last day data from the male and female rats designated for reproduction evaluations were reported with the subchronic toxicity animals. Body weights and clinical observations collected during the cohabitation and post-mating periods are reported in the Reproductive Toxicology section; Dose volumes administered during the cohabitation and post-mating periods are documented in study records.

Day 90 Last day of test substance administration for male and female rats designated for one-month and three-month recovery periods.

Day 91
- Last day of body weight and food consumption data collection for male and female rats designated for the subchronic toxicity evaluation.
- Last day of test substance administration for male rats designated for the subchronic toxicity evaluation.

Day 92
- Male rats designated for the subchronic toxicity evaluation were sacrificed.
- Last day of test substance administration for female rats designated for the subchronic toxicity evaluation.

Day 93 Female rats designated for the subchronic toxicity evaluation were sacrificed.

Day 126
- Last day of body weight and food consumption data collection for rats designated for the one-month recovery period.
- Last day of food consumption data collection for rats designated for the three-month recovery period.


Day 127 Male and female rats designated for the one-month recovery were sacrificed.

Day 182 Male and female rats designated for blood fluorine level evaluation were sacrificed.

Company Sanitized. Does not contain TSCA CBI

FIGURE 1


MEAN BODY WEIGHTS OF MALE RATS



Company Sanitized. Does not contain TSCA CBI

FIGURE 2


MEAN BODY WEIGHTS OF FEMALE RATS



Company Sanitized. Does not contain TSCA CBI

FIGURE 3

MEAN FORELIMB GRIP STRENGTH FOR MALE RATS




Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 4

MEAN FORELIMB GRIP STRENGTH FOR FEMALE RATS




Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 5

MEAN HINDLIMB GRIP STRENGTH FOR MALE RATS




Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 6

MEAN HINDLIMB GRIP STRENGTH FOR FEMALE RATS




Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 7

MOTOR ACTIVITY ASSESSMENT: MEAN TOTAL DURATION OF MOVEMENT FOR MALE RATS




Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 8

MOTOR ACTIVITY ASSESSMENT: MEAN TOTAL DURATION OF MOVEMENT FOR FEMALE RATS




Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 9

MOTOR ACTIVITY ASSESSMENT: MEAN TOTAL NUMBER OF MOVEMENTS FOR MALE RATS




Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

FIGURE 10

MOTOR ACTIVITY ASSESSMENT: MEAN TOTAL NUMBER OF MOVEMENTS FOR FEMALE RATS



Error bars represent the standard deviation.

Company Sanitized. Does not contain TSCA CBI

APPENDICES

Company Sanitized. Does not contain TSCA CBI

APPENDICES

EXPLANATORY NOTES

Critical Dates

Day 72 Last day data from the male and female rats designated for reproduction evaluations were reported with the subchronic toxicity animals. Body weights and clinical observations collected during the cohabitation and post-mating periods are reported in the Reproductive Toxicology section; Dose volumes administered during the cohabitation and post-mating periods are documented in study records.

Day 90 Last day of test substance administration for male and female rats designated for one-month and three-month recovery periods.

Day 91
- Last day of body weight and food consumption data collection for male and female rats designated for the subchronic toxicity evaluation.
- Last day of test substance administration for male rats designated for the subchronic toxicity evaluation.

Day 92
- Male rats designated for the subchronic toxicity evaluation were sacrificed.
- Last day of test substance administration for female rats designated for the subchronic toxicity evaluation.

Day 93 Female rats designated for the subchronic toxicity evaluation were sacrificed.

Day 126
- Last day of body weight and food consumption data collection for rats designated for the one-month recovery period.
- Last day of food consumption data collection for rats designated for the three-month recovery period.

Day 127 Male and female rats designated for the one-month recovery were sacrificed.

Day 182 Male and female rats designated for blood fluorine level evaluation were sacrificed.

Abbreviations

mg/kg = mg/kg/day
g/anm/day = grams/animal/day

Note

Absence of data indicates the animal was not alive at the time of data collection;
NM (not measured) may be reported if an animal died on the day of a scheduled weighing.

Company Sanitized. Does not contain TSCA CBI

APPENDIX A

ANALYTICAL DATA

Company Sanitized. Does not contain TSCA CBI

Table I. Recovery of H-25425 Added to Dosing Vehicle

Sample Type	mg/ml H-25425 Nominal	Measured		Percent Nominal
RECOVERY[A]	1.96	1.48		75.5
RECOVERY[B]	2.17	1.61		74.2
RECOVERY[C]	2.70	1.85		68.5
RECOVERY[D]	2.45	1.92		78.4
			Mean	***74.2±4.2, C.V. 6%***
RECOVERY[A]	19.1	16.4		85.9
RECOVERY[C]	19.4	17.1		88.1
RECOVERY[D]	20.7	17.4		84.1
			Mean	***86.0 ±2.0, C.V. 2%***
RECOVERY[A]	189	175		92.6
RECOVERY[C]	198	191		96.5
RECOVERY[D]	192	171		89.1
			Mean	***92.8 ±3.7, C.V. 4%***

(A) Processed with homogeneity/concentration verification samples from dosing prepared on test day 2 (October 17, 2002).

(B) Processed with homogeneity/concentration verification samples from dosing prepared on test day 8 (October 23, 2002).

(C) Processed with concentration verification samples from dosing prepared on test day 42 (November 26, 2002).

(D) Processed with concentration verification samples from dosing prepared on test day 86 (January 9, 2003).

Company Sanitized. Does not contain TSCA CBI

Table II. Homogeneity/Concentration Verification and Stability of H-25425 in Dosing Suspensions

Sample Type	mg/mL H-25425 Nominal	Measured	Percent Nominal
Test day 2 Homogeneity			
CONTROL	0.00	ND(A)	----
TOP	2.00(B)	1.36	68.0
MIDDLE	2.00(B)	1.87	93.5
BOTTOM	2.00(B)	2.00	100.0
		Mean(C): 1.74 ± 0.34	***(87.0%)***
		C.V. 19%	
TOP	20.0(B)	19.0	95.0
MIDDLE	20.0(B)	20.8	104.0
BOTTOM	20.0(B)	21.3	106.5
		Mean(C): 20.4 ± 1.2	***(102.0%)***
		C.V. 6%	
TOP	200	187	93.5
MIDDLE	200	188	94.0
BOTTOM	200	191	95.5
		Mean(C): 189 ± 2.1	***(94.5%)***
		C.V. 1%	
5 HOUR(D)	2.00(B)	1.83	91.5
	20.0(B)	21.7	108.5
	200	196	98.0
Test day 9 Homogeneity			
CONTROL	0.00	ND(A)	----
TOP	2.00(B)	1.87	93.5
MIDDLE	2.00(B)	1.97	98.5
BOTTOM	2.00(B)	1.91	95.5
		Mean(C): 1.92 ± 0.05	***(96.0%)***
		C.V. 2%	

(A) Denotes not detected.
(B) All reported results corrected based on recovery of the spiked sample (refer to Table I).
(C) The average measured concentration, average percent of nominal (in parentheses), standard deviation, and coefficient of variation of top, middle, and bottom.
(D) Stability samples held 5 hours a room temperature.

Company Sanitized. Does not contain TSCA CBI

Table III. Concentration Verification of H-25425 in Dosing suspensions

Preparation Day / Sample Type	mg/mL H-25425 Nominal		Measured	Percent Nominal
Test day 42				
Concentration Verification[A]				
Control	0.0		ND[B]	----
	2.00-1[C]		2.35	117.5
	2.00-2[C]		2.36	118.0
		Mean[D]:	***2.36 ± 0.10***	***(118.0)***
			C.V. 0.4%	
	20.0-1[C]		20.5	102.5
	20.0-1[C]		20.8	104.0
		Mean[D]:	***20.7 ± 0.16***	***(103.5)***
			C.V. 1%	
	200-1		190	95.0
	200-2		193	96.5
		Mean[D]:	***192 ± 2.1***	***(96.0)***
			C.V. 1%	
Test day 86				
Concentration Verification[A]				
Control	0.0		ND[B]	----
	2.00-1[C]		2.03	101.5
	2.00-2[C]		2.04	102.0
		Mean[D]:	***2.04 ± 0.01***	***(102.0)***
			C.V. 0.5%	
	20.0-1[C]		19.6	98.0
	20.0-1[C]		21.8	109.0
		Mean[D]:	***20.7 ± 1.5***	***(103.5)***
			C.V. 7%	
	200-1[C]		209	104.5
	200-1[C]		203	101.5
		Mean[D]:	***206 ± 4.0***	***(103.0)***
			C.V. 2%	

(A) Duplicate samples per level were analyzed. Mean, S.D. and C.V. calculated to verify uniformity of mixture.
(B) Denotes not detected.
(C) All reported results corrected based on recovery of the spiked sample (refer to Table I).
(D) Mean result for analyses on duplicate samples.

Company Sanitized. Does not contain TSCA CBI

Figure 1
Representative Analytical Calibration Curves




Figure 1a: Calibration curve showing linear fit (line) to replicate peak height measurements (squares) for calibration solutions of H-25425 diluted with THF over a concentration range of 1.897 to 8.672 mg/mL.

Company Sanitized. Does not contain TSCA CBI

Figure 2
Representative HPLC/GPC/RI Chromatography Chromatograms




Figure 2a: Representative HPLC/GPC/RI chromatogram of 0.00 mg/mL dosing suspension of H-25425.




Figure 2b: Representative HPLC/GPC/RI chromatogram of 5.962 mg/mL analytical reference solution of H-25425.

Company Sanitized. Does not contain TSCA CBI

Figure 2 (continued)
Representative HPLC/GPC/RI Chromatography Chromatograms




Figure 2c: Representative HPLC/GPC/RI chromatogram of 200 mg/mL dosing suspension diluted to nominal concentration of 6.00 mg/mL of H-25425. The measured concentration of the representative solution is 190 mg/mL.




Figure 2d: Representative HPLC/GPC/RI chromatogram of 198 mg/mL spiked dosing suspension diluted to nominal concentration of 6.00 mg/mL of H-25425. The measured concentration of the representative solution is 193 mg/mL.

Company Sanitized. Does not contain TSCA CBI

APPENDIX B

INDIVIDUAL DOSE VOLUMES

Company Sanitized. Does not contain TSCA CBI

INDIVIDUAL DOSE VOLUMES

EXPLANATORY NOTES

Critical Dates

Day 72 Last day data from the male and female rats designated for reproduction evaluations were reported with the subchronic toxicity animals. Body weights and clinical observations collected during the cohabitation and post-mating periods are reported in the Reproductive Toxicology section; Dose volumes administered during the cohabitation and post-mating periods are documented in study records.

Day 90 Last day of test substance administration for male and female rats designated for one-month and three-month recovery periods.

Day 91
- Last day of body weight and food consumption data collection for male and female rats designated for the subchronic toxicity evaluation.
- Last day of test substance administration for male rats designated for the subchronic toxicity evaluation.

Day 92
- Male rats designated for the subchronic toxicity evaluation were sacrificed.
- Last day of test substance administration for female rats designated for the subchronic toxicity evaluation.

Day 93 Female rats designated for the subchronic toxicity evaluation were sacrificed.

Day 126
- Last day of body weight and food consumption data collection for rats designated for the one-month recovery period.
- Last day of food consumption data collection for rats designated for the three-month recovery period.

Day 127 Male and female rats designated for the one-month recovery were sacrificed.

Day 182 Male and female rats designated for blood fluorine level evaluation were sacrificed.

Abbreviations

mg/kg = mg/kg/day

Note

Absence of data indicates the animal was not alive at the time of data collection.

Company Sanitized. Does not contain TSCA CBI

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, I 0 mg/kg												
665047	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665049	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665070	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.8	1.8	1.8	1.8	1.8
665130	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665076	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665015	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665068	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665148	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665016	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665086	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.3	1.3	1.3	1.3	1.3
665023	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665072	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665151	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665164	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665154	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665144	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665104	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665044	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665141	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.3	1.3	1.3	1.3	1.3
665135	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665005	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.5	1.5	1.5	1.5	1.5
665075	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665091	1.2	1.2	1,2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665040	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665069	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665029	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665000	1.2	1.2	1.2	1.2	1.2	NM	1.2	1.5	1.5	1.5	1.5	1.5
665166	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665012	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
664996	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
664994	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665046	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665021	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665087	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665079	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.6	1.6	1.6	1.6	1.6
665042	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665098	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665149	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.6	1.6	1.6	1.6	1.6

Key: NM = Not Measurable; error in recording dose volume in database but rat believed to have received correct dose volume.

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, I 0 mg/kg												
665081	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665159	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665043	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665064	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665121	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665106	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665008	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, III 10 mg/kg												
665053	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665074	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665128	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665080	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
664993	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665131	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665060	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
664995	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665136	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665033	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665132	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665156	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665061	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665145	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665019	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665153	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665037	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665163	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665001	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665126	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665125	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665017	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665071	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665032	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
664997	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665110	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665041	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665058	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665113	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665056	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665025	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665038	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665006	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665167	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665020	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, V 100 mg/kg												
665122	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665155	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665073	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.7	1.7	1.7	1.7	1.7
665089	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665119	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665137	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665103	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665143	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665054	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665035	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665048	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665030	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665028	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665052	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665150	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665116	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665034	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665051	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665083	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665124	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665078	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665036	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665085	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665092	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665004	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665140	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665114	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665139	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665111	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665055	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665066	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665039	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665003	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665088	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665147	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, VII 1000 mg/kg												
665160	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6
665096	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665082	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665107	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665152	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665120	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
664999	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665026	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665162	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665027	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665084	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665142	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665118	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665108	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665024	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665050	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665134	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665022	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665105	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665102	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665161	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665133	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665157	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665093	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665059	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665123	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665018	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665065	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665063	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665090	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665057	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665011	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665109	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
664998	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665077	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665158	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.4	1.4	1.4	1.4	1.4
665002	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665067	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Male, VII 1000 mg/kg												
665095	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4
665031	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665146	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665062	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.5	1.5	1.5	1.5	1.5
665138	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3
665112	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5
665007	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.6	1.6	1.6	1.6	1.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, I 0 mg/kg												
665047	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665049	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665070	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2	2.2	2.2
665130	1.5	1.5	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
665076	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665015	1.5	1.5	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
665068	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665148	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
665016	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
665086	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.8	1.8	1.8
665023	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665072	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665151	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665164	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665154	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665144	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665104	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
665044	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665141	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665135	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665005	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665075	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665091	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665040	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
665069	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665029	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
665000	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665166	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.2	2.2	2.2
665012	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
664996	1.3	1.3	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
664994	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665046	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665021	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
665087	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665079	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665042	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
665098	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665149	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, I 0 mg/kg												
665081	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
665159	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665043	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665064	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665121	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665106	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665008	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, III 10 mg/kg												
665053	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665074	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665128	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665080	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
664993	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665131	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665060	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
664995	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665136	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665033	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665132	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5
665156	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665061	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
665145	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665019	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6
665153	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665037	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665163	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
665001	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665126	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
665125	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
665017	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665071	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665032	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
664997	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665110	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665041	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665058	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665113	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665056	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6
665025	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
665038	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665006	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665167	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665020	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, V 100 mg/kg												
665122	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665155	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665073	1.7	1.7	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.3	2.3	2.3
665089	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
665119	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665137	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665103	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665143	1.6	1.6	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1
665054	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665035	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6
665048	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665030	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665028	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665052	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665150	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665116	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
665034	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665051	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8
665083	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665124	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665078	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665036	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7
665085	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665092	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665004	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665140	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665114	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665139	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665111	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665055	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665066	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665039	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665003	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665088	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6
665147	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, VII 1000 mg/kg												
665160	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665096	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665082	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665107	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665152	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665120	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
664999	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665026	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9	1.9	1.9
665162	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.1	2.1	2.1
665027	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
665084	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665142	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665118	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.8	NM	1.8
665108	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665024	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665050	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665134	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665022	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665105	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665102	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665161	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665133	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.9	1.9	1.9
665157	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665093	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665059	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665123	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665018	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665065	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665063	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665090	1.3	1.3	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665057	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9	1.9	1.9
665011	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665109	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
664998	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665077	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9
665158	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.8	1.8	1.8
665002	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665067	1.4	1.4	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9	1.9	1.9

Key: NM = Not Measurable; partial dose given

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Male, VII 1000 mg/kg												
665095	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.8	1.8	1.8
665031	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665146	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665062	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	2.0	2.0	2.0
665138	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.7	1.7	1.7
665112	1.5	1.5	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0
665007	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0	2.0	2.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, I 0 mg/kg												
665047	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665049	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665070	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.7
665130	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
665076	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665015	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
665068	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665148	2.1	2.1	2.1	2.1	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5
665016	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665086	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1
665023	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665072	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665151	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665164	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665154	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665144	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665104	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665044	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665141	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
665135	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665005	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665075	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665091	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
665040	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665069	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665029	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
665000	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665166	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5
665012	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
664996	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
664994	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665046	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665021	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665087	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665079	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
665042	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665098	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665149	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, I 0 mg/kg												
665081	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665159	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665043	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665064	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665121	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665106	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665008	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, III 10 mg/kg												
665053	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665074	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
665128	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
665080	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
664993	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665131	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665060	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
664995	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665136	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
665033	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1
665132	1.5	1.5	1.5	1.5	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665156	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665061	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665145	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665019	1.6	1.6	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
665153	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665037	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665163	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665001	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665126	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665125	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665017	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665071	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665032	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
664997	1.9	1.9	1.9	1.9	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665110	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665041	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
665058	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665113	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
665056	1.6	1.6	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
665025	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665038	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665006	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665167	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665020	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, V 100 mg/kg												
665122	1.9	1.9	1.9	1.9	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665155	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665073	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7
665089	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665119	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665137	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665103	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665143	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
665054	1.8	1.8	1.8	1.8	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665035	1.6	1.6	1.6	1.6	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
665048	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1
665030	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665028	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665052	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665150	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.6
665116	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
665034	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665051	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665083	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665124	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665078	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665036	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665085	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5
665092	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
665004	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665140	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665114	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665139	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665111	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665055	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665066	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665039	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665003	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665088	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.9
665147	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, VII 1000 mg/kg												
665160	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4
665096	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665082	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665107	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665152	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665120	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
664999	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665026	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665162	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665027	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665084	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
665142	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.3
665118	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665108	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665024	1.7	1.7	1.7	1.7	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665050	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665134	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665022	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8
665105	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
665102	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665161	1.8	1.8	1.8	1.8	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1
665133	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665157	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665093	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.9
665059	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2
665123	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665018	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665065	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665063	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665090	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.0
665057	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665011	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4
665109	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
664998	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
665077	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665158	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1
665002	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665067	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Male, VII 1000 mg/kg												
665095	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	2.1
665031	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665146	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665062	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3
665138	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	2.0
665112	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2
665007	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, I 0 mg/kg												
665047	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3
665049	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665070	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
665130	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
665076	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665015	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665068	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665148	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
665016	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665086	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
665023	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665072	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665151	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
665164	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665154	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665144	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
665104	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665044	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665141	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665135	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665005	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
665075	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
665091	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
665040	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665069	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665029	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665000	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665166	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
665012	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
664996	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
664994	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665046	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665021	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665087	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665079	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
665042	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665098	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665149	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, I 0 mg/kg												
665081	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665159	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665043	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
665064	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665121	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665106	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665008	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, III 10 mg/kg												
665053	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665074	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665128	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6
665080	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
664993	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665131	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665060	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
664995	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665136	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665033	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
665132	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8
665156	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665061	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665145	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665019	1.9	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0
665153	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665037	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
665163	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665001	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3	2.3	2.3	2.3	2.3
665126	2.0	2.0	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2
665125	2.0	2.0	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2
665017	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665071	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665032	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
664997	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665110	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665041	1.9	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0
665058	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
665113	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665056	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1
665025	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665038	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665006	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
665167	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
665020	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, V 100 mg/kg												
665122	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665155	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665073	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
665089	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665119	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665137	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665103	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665143	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665054	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665035	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
665048	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665030	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665028	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
665052	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665150	2.6	2.6	2.6	2.6	2.6	2.6	2.8	2.8	2.8	2.8	2.8	2.8
665116	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665034	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665051	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665083	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665124	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
665078	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665036	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665085	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6
665092	1.9	1.9	1.9	1.9	1.9	1.9	2.1	2.1	2.1	2.1	2.1	2.1
665004	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665140	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665114	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665139	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665111	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665055	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665066	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665039	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
665003	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665088	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
665147	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, VII 1000 mg/kg												
665160	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665096	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665082	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665107	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665152	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665120	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
664999	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665026	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665162	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665027	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665084	1.9	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0
665142	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665118	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665108	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665024	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665050	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665134	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665022	1.8	1.8	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9
665105	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665102	2.0	2.0	2.0	2.0	2.0	2.0	2.2	2.2	2.2	2.2	2.2	2.2
665161	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665133	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665157	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665093	1.9	1.9	1.9	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0
665059	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665123	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665018	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665065	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665063	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665090	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665057	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
665011	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
665109	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
664998	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665077	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665158	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665002	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5
665067	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Male, VII 1000 mg/kg												
665095	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2
665031	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665146	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4	2.4	2.4
665062	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4
665138	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1
665112	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3
665007	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5	2.5	2.5	2.5	2.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, I 0 mg/kg												
665047	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665049	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665070	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.1	3.1	3.1	3.1
665130	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665076	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665015	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.8	2.8	2.8	2.8
665068	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665148	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9
665016	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665086	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665023	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665072	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
665151	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665164	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665154	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665144	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665104	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665044	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665141	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665135	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
665005	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.9	2.9	2.9	2.9
665075	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665091	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9
665040	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665069	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665029	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665000	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665166	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9
665012	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
664996	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
664994	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665046	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665021	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665087	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665079	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.9	2.9	2.9	2.9
665042	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665098	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665149	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, I 0 mg/kg												
665081	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665159	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665043	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665064	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665121	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665106	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665008	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, III 10 mg/kg												
665053	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665074	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665128	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.6	2.6	2.6	2.6
665080	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
664993	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665131	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665060	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
664995	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665136	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665033	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665132	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
665156	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665061	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665145	2.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665019	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665153	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665037	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665163	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665001	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6
665126	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665125	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665017	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665071	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665032	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
664997	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665110	2.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665041	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2
665058	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665113	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665056	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2
665025	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665038	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665006	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665167	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665020	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, V 100 mg/kg												
665122	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665155	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7
665073	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0
665089	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665119	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665137	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4
665103	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.6	2.6	2.6	2.6
665143	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665054	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665035	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1
665048	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.4	2.4	2.4	2.4
665030	2.2	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665028	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665052	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665150	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0
665116	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665034	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665051	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665083	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665124	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665078	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665036	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665085	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665092	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2
665004	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665140	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665114	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665139	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665111	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665055	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665066	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665039	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665003	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665088	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.1	2.1	2.1	2.1
665147	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, VII 1000 mg/kg												
665160	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665096	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665082	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665107	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665152	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665120	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
664999	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665026	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665162	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665027	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665084	2.0	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665142	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665118	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665108	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665024	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665050	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665134	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665022	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
665105	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665102	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665161	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665133	2.3	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665157	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665093	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2	2.2	2.2
665059	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4
665123	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665018	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665065	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665063	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665090	2.1	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665057	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665011	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8
665109	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
664998	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665077	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5
665158	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665002	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665067	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Male, VII 1000 mg/kg												
665095	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3	2.3	2.3
665031	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665146	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
665062	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7
665138	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665112	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665007	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, I 0 mg/kg												
665047	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665049	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665070	3.1	3.1	3.1	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.3
665130	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
665076	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665015	2.8	2.8	2.8	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
665068	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665148	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
665016	2.4	2.4	2.4	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665086	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665023	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665072	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665151	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665164	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665154	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665144	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665104	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665044	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665141	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665135	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665005	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
665075	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665091	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
665040	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665069	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665029	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665000	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665166	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
665012	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
664996	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
664994	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665046	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665021	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665087	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.5	2.5
665079	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
665042	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665098	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665149	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, I 0 mg/kg												
665081	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665159	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665043	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665064	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665121	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665106	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665008	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, III 10 mg/kg												
665053	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665074	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
665128	2.6	2.6	2.6	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1	3.1
665080	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
664993	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665131	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665060	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
664995	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665136	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665033	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665132	1.9	1.9	1.9	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
665156	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665061	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665145	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665019	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665153	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665037	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665163	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665001	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665126	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665125	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665017	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665071	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665032	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
664997	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665110	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665041	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665058	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665113	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
665056	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665025	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665038	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665006	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665167	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665020	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, V 100 mg/kg												
665122	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665155	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665073	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2	3.2
665089	2.6	2.6	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665119	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665137	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665103	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665143	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665054	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665035	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.2	2.2
665048	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665030	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665028	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665052	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665150	3.0	3.0	3.0	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.3	3.3
665116	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665034	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665051	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665083	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665124	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665078	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665036	2.2	2.2	2.2	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.3	2.3
665085	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0	3.0
665092	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3
665004	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665140	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665114	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665139	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665111	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665055	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665066	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665039	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665003	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665088	2.1	2.1	2.1	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3
665147	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, VII 1000 mg/kg												
665160	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665096	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665082	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665107	2.6	2.6	2.6	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665152	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665120	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
664999	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665026	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665162	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	3.0	3.0
665027	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665084	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3	2.3
665142	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665118	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665108	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665024	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665050	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665134	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665022	2.0	2.0	2.0	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1	2.1
665105	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665102	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665161	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665133	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665157	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.5	2.5
665093	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665059	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665123	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665018	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665065	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665063	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665090	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.5	2.5
665057	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665011	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665109	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
664998	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665077	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665158	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665002	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
665067	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Male, VII 1000 mg/kg												
665095	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.4
665031	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7	2.7
665146	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
665062	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665138	2.2	2.2	2.2	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665112	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6
665007	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, I 0 mg/kg												
665047	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665049	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665070	3.3	3.3	3.3	3.3	3.3	3.4	3.4	3.4	3.4	3.4	3.4	3.4
665130	3.0	3.0	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.1
665076	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665015	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
665068	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665148	3.1	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2	3.2	3.2
665016	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665086	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665023	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665072	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665151	2.8	2.8	2.8	2.8	2.8	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665164	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665154	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665144	2.9											
665104	2.7											
665044	2.6											
665141	2.4											
665135	2.8											
665005	3.1											
665075	2.5											
665091	3.1											
665040	2.4											
665069	2.8											
665029	2.5											
665000	2.7											
665166	3.0											
665012	2.6											
664996	2.4											
664994	2.5											
665046	2.7											
665021	2.5											
665087	2.5											
665079	3.1											
665042	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
665098	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665149	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, I 0 mg/kg												
665081	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665159	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665043	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665064	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665121	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665106	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665008	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, III 10 mg/kg												
665053	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665074	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665128	3.1	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2	3.2	3.2
665080	2.8	2.8	2.8	2.8	2.8	2.5	2.5	2.5	2.5	2.5	2.5	2.5
664993	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665131	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665060	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
664995	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665136	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665033	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665132	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
665156	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665061	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665145	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665019	2.5	2.5	2.5	2.5	2.5	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665153	2.6											
665037	2.8											
665163	2.6											
665001	2.7											
665126	2.6											
665125	2.5											
665017	2.5											
665071	2.6											
665032	2.4											
664997	2.7											
665110	2.6											
665041	2.3											
665058	2.9											
665113	3.0											
665056	2.4											
665025	2.5											
665038	2.7											
665006	2.8											
665167	2.4											
665020	2.7											

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] ale

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, V 100 mg/kg												
665122	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665155	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665073	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
665089	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665119	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665137	2.6	2.6	2.6	2.6	2.6	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665103	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665143	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665054	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665035	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.2
665048	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665030	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665028	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665052	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665150	3.3	3.3	3.3	3.3	3.3	3.4	3.4	3.4	3.4	3.4	3.4	3.4
665116	2.4											
665034	2.8											
665051	2.4											
665083	2.4											
665124	2.1											
665078	2.7											
665036	2.3											
665085	3.0											
665092	2.3											
665004	2.8											
665140	2.7											
665114	2.5											
665139	2.7											
665111	2.5											
665055	2.5											
665066	2.5											
665039	2.6											
665003	2.8											
665088	2.3											
665147	2.6											

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, VII 1000 mg/kg												
665160	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665096	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665082	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665107	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665152	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665120	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
664999	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665026	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665162	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665027	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665084	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665142	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665118	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665108	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665024	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665050	2.9											
665134	2.4											
665022	2.1											
665105	2.4											
665102	2.5											
665161	2.6											
665133	2.7											
665157	2.5											
665093	2.2											
665059	2.5											
665123	2.8											
665018	2.8											
665065	2.9											
665063	2.8											
665090	2.5											
665057	2.9											
665011	2.9											
665109	2.8											
664998	2.4											
665077	2.6											
665158	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665002	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665067	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.7

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Male, VII 1000 mg/kg												
665095	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5	2.5
665031	2.7	2.7	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665146	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665062	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665138	2.3	2.3	2.3	2.3	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.4
665112	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665007	2.9	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91
Male, I 0 mg/kg								
665047	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8
665049	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665070	3.5	3.5	3.5	3.5	3.5	3.5	3.5	3.6
665130	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.1
665076	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7
665015	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.3
665068	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665148	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.3
665016	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665086	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6
665023	3.0	3.0	3.0	3.0	3.0	3.0	3.0	
665072	3.0	3.0	3.0	3.0	3.0	3.0	3.0	
665151	2.8	2.8	2.8	2.8	2.8	2.8	2.8	
665164	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
665154	3.1	3.1	3.1	3.1	3.1	3.1	3.1	
665144								
665104								
665044								
665141								
665135								
665005								
665075								
665091								
665040								
665069								
665029								
665000								
665166								
665012								
664996								
664994								
665046								
665021								
665087								
665079								
665042	2.4	2.4	2.4	2.4	2.4	2.4	2.4	
665098	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
665149	3.0	3.0	3.0	3.0	3.0	3.0	3.0	

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91
Male, I 0 mg/kg								
665081	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
665159	2.8	2.8	2.8	2.8	2.8	2.8	2.8	
665043	3.0	3.0	3.0	3.0	3.0	3.0	3.0	
665064	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
665121	2.8	2.8	2.8	2.8	2.8	2.8	2.8	
665106	3.1	3.1	3.1	3.1	3.1	3.1	3.1	
665008	3.0	3.0	3.0	3.0	3.0	3.0	3.0	

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91
Male, III 10 mg/kg								
665053	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1
665074	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2
665128	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.2
665080	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8
664993	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6
665131	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665060	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
664995	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7
665136	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665033	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.7
665132	2.1	2.1	2.1	2.1	2.1	2.1	2.1	
665156	2.9	2.9	2.9	2.9	2.9	2.9	2.9	
665061	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
665145	2.6	2.6	2.6	2.6	2.6	2.6	2.6	
665019	2.6	2.6	2.6	2.6	2.6	2.6	2.6	
665153								
665037								
665163								
665001								
665126								
665125								
665017								
665071								
665032								
664997								
665110								
665041								
665058								
665113								
665056								
665025								
665038								
665006								
665167								
665020								

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91
Male, V 100 mg/kg								
665122	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665155	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665073	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.3
665089	3.0	3.0	3.0	3.0	3.0	3.0	3.0	2.9
665119	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6
665137	2.6	2.6	2.6	2.6	2.6	2.6	2.6	2.6
665103	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
665143	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.0
665054	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9
665035	2.2	2.2	2.2	2.2	2.2	2.2	2.2	2.3
665048	2.6	2.6	2.6	2.6	2.6	2.6	2.6	
665030	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
665028	3.0	3.0	3.0	3.0	3.0	3.0	3.0	
665052	2.9	2.9	2.9	2.9	2.9	2.9	2.9	
665150	3.4	3.4	3.4	3.4	3.4	3.4	3.4	
665116								
665034								
665051								
665083								
665124								
665078								
665036								
665085								
665092								
665004								
665140								
665114								
665139								
665111								
665055								
665066								
665039								
665003								
665088								
665147								

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91
Male, VII 1000 mg/kg								
665160	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0
665096	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0
665082	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8
665107	2.9	2.9	2.9	2.9	2.9	2.9	2.9	3.0
665152	3.0	3.0	3.0	3.0	3.0	3.0	3.0	3.1
665120	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
664999	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
665026	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8
665162	3.1	3.1	3.1	3.1	3.1	3.1	3.1	3.2
665027	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7
665084	2.5	2.5	2.5	2.5	2.5	2.9[a]	2.5	
665142	2.9	2.9	2.9	2.9	2.9	2.9	2.9	
665118	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
665108	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
665024	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
665050								
665134								
665022								
665105								
665102								
665161								
665133								
665157								
665093								
665059								
665123								
665018								
665065								
665063								
665090								
665057								
665011								
665109								
664998								
665077								
665158	2.4	2.4	2.4	2.4	2.4	2.4	2.4	
665002	3.0	3.0	3.0	3.0	3.0	3.0	3.0	
665067	2.7	2.7	2.7	2.7	2.7	2.7	2.7	

[a] Rat was inadvertently give an additional 0.4 mL.

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] male

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91
Male, VII 1000 mg/kg								
665095	2.5	2.5	2.5	2.5	2.5	2.5	2.5	
665031	2.8	2.8	2.8	2.8	2.8	2.8	2.8	
665146	2.9	2.9	2.9	2.9	2.9	2.9	2.9	
665062	3.0	3.0	3.0	3.0	3.0	3.0	3.0	
665138	2.3	2.3	2.3	2.3	2.3	2.3	2.3	
665112	2.7	2.7	2.7	2.7	2.7	2.7	2.7	
665007	3.0	3.0	3.0	3.0	3.0	3.0	3.0	

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, II 0 mg/kg												
665211	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665271	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665178	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665317	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665230	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665225	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665174	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665319	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665221	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665278	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665176	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665283	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665297	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8
665301	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665269	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665220	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665334	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665257	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665175	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665336	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665192	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665232	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665307	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665246	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665289	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665264	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665185	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665206	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665306	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665226	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665198	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665249	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665284	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665240	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665201	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665197	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665256	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665323	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665276	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, II 0 mg/kg												
665228	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665260	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665189	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665204	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665327	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665203	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, IV 10 mg/kg												
665308	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665215	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
665277	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665241	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665236	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665324	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665332	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665239	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665182	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665268	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665218	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665309	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665177	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665202	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665235	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665212	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665180	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665292	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665187	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665205	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665263	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665210	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665181	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665248	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665293	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665329	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665290	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665253	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665286	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665281	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665186	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665330	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665294	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665244	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
665258	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, VI 100 mg/kg												
665295	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665251	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665300	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665340	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665259	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665341	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665199	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665238	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665250	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665170	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665313	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665233	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665216	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665266	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665270	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665338	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8
665219	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665267	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665325	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665331	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665217	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665227	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665262	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665247	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665243	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665312	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665298	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665207	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665273	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665274	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665272	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665195	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665314	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665316	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665173	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, VIII 1000 mg/kg												
665234	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665242	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665183	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665261	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665291	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665337	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665333	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665200	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665310	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665326	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665302	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665179	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665287	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665172	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665194	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665296	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
665193	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665320	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665315	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665318	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665279	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665224	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665254	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665245	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665322	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665214	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665321	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
665171	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665265	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1
665169	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665191	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665231	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665288	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665282	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1
665275	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665229	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665237	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665209	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665335	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]tem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 0	Gavage ml Day 1	Gavage ml Day 2	Gavage ml Day 3	Gavage ml Day 4	Gavage ml Day 5	Gavage ml Day 6	Gavage ml Day 7	Gavage ml Day 8	Gavage ml Day 9	Gavage ml Day 10	Gavage ml Day 11
Female, VIII 1000 mg/kg												
665303	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
665328	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665299	0.8	0.8	0.8	0.8	0.8	0.8	0.8	1.0	1.0	1.0	1.0	1.0
665255	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665213	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0
665280	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1	1.1	1.1

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, II 0 mg/kg												
665211	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665271	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665178	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665317	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665230	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665225	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665174	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665319	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665221	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665278	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665176	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665283	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665297	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9
665301	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665269	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665220	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665334	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665257	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665175	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665336	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665192	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665232	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665307	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4
665246	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665289	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665264	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665185	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665206	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665306	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665226	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665198	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665249	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665284	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665240	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665201	0.9	0.9	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665197	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665256	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665323	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665276	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] Fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, II 0 mg/kg												
665228	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4
665260	1.1	1.1	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3
665189	1.1	1.1	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3
665204	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665327	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665203	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, IV 10 mg/kg												
665308	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665215	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1
665277	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665241	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665236	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665324	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665332	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665239	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665182	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665268	0.9	0.9	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665218	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665309	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665177	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665202	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665235	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665212	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665180	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665292	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4
665187	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665205	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665263	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665210	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665181	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665248	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665293	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665329	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665290	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
665253	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
665286	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665281	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
665186	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665330	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665294	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665244	0.7	0.7	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
665258	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, VI 100 mg/kg												
665295	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665251	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665300	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665340	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665259	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665341	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665199	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665238	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665250	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665170	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1
665313	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665233	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665216	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665266	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665270	0.9	0.9	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665338	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9
665219	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1
665267	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665325	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665331	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665217	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665227	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665262	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665247	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665243	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665312	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665298	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665207	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4
665273	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665274	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665272	0.9	0.9	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665195	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.2	1.2	1.2
665314	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665316	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
665173	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, VIII 1000 mg/kg												
665234	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665242	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665183	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665261	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665291	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665337	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
665333	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665200	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665310	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665326	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665302	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665179	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665287	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665172	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665194	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
665296	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9
665193	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665320	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1
665315	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
665318	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665279	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665224	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3
665254	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665245	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665322	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665214	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665321	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.0
665171	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665265	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4
665169	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665191	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665231	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665288	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665282	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665275	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665229	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665237	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665209	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1
665335	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 12	Gavage ml Day 13	Gavage ml Day 14	Gavage ml Day 15	Gavage ml Day 16	Gavage ml Day 17	Gavage ml Day 18	Gavage ml Day 19	Gavage ml Day 20	Gavage ml Day 21	Gavage ml Day 22	Gavage ml Day 23
Female, VIII 1000 mg/kg												
665303	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.1	1.1	1.1
665328	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665299	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665255	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3
665213	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2
665280	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.3	1.3	1.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, II 0 mg/kg												
665211	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
665271	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665178	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665317	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665230	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665225	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665174	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665319	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665221	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5
665278	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665176	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665283	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665297	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665301	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665269	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665220	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665334	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665257	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665175	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665336	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665192	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665232	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.2
665307	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665246	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665289	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665264	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665185	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665206	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665306	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665226	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665198	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665249	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665284	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665240	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665201	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665197	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665256	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665323	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665276	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, II 0 mg/kg												
665228	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665260	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665189	1.3	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665204	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665327	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665203	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted]tem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, IV 10 mg/kg												
665308	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665215	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665277	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665241	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665236	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
665324	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665332	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665239	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665182	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.2
665268	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665218	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665309	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665177	1.1	1.1	1.1	1.1	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665202	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665235	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665212	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665180	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665292	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665187	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665205	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665263	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665210	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665181	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665248	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
665293	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665329	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665290	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6
665253	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6
665286	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665281	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1
665186	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665330	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665294	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665244	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1
665258	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, VI 100 mg/kg												
665295	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665251	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665300	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665340	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665259	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665341	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665199	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665238	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665250	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665170	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665313	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665233	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665216	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665266	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665270	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665338	0.9	0.9	0.9	0.9	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665219	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665267	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665325	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665331	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665217	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665227	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665262	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665247	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665243	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665312	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665298	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665207	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665273	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665274	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665272	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665195	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665314	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665316	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665173	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted]tem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, VIII 1000 mg/kg												
665234	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665242	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665183	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665261	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.4
665291	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665337	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665333	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665200	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665310	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665326	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665302	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665179	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665287	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665172	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665194	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665296	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.9	1.0
665193	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.5
665320	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665315	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665318	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665279	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5
665224	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665254	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665245	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665322	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665214	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665321	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665171	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665265	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6
665169	1.0	1.0	1.0	1.0	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665191	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665231	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665288	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665282	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4
665275	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665229	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665237	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.2
665209	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665335	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 24	Gavage ml Day 25	Gavage ml Day 26	Gavage ml Day 27	Gavage ml Day 28	Gavage ml Day 29	Gavage ml Day 30	Gavage ml Day 31	Gavage ml Day 32	Gavage ml Day 33	Gavage ml Day 34	Gavage ml Day 35
Female, VIII 1000 mg/kg												
665303	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665328	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665299	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665255	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665213	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3
665280	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, II 0 mg/kg												
665211	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665271	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665178	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665317	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665230	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665225	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665174	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665319	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665221	1.5	1.5	1.5	1.5	1.5	1.5	1.4	1.4	1.4	1.4	1.4	1.4
665278	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665176	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665283	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665297	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665301	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665269	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665220	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665334	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665257	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665175	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665336	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665192	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665232	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665307	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6
665246	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665289	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665264	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665185	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665206	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665306	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665226	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665198	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665249	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665284	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665240	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665201	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665197	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665256	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665323	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665276	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, II 0 mg/kg												
665228	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6
665260	1.4	1.4	1.4	1.4	1.4	1.4	1.6	1.6	1.6	1.6	1.6	1.6
665189	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665204	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665327	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665203	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, IV 10 mg/kg												
665308	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665215	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665277	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665241	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665236	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665324	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665332	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665239	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665182	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665268	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3	1.3	1.3	1.3
665218	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665309	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665177	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665202	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665235	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665212	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665180	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665292	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6
665187	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665205	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665263	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665210	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665181	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665248	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6
665293	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665329	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665290	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665253	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665286	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665281	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665186	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665330	1.2	1.2	1.2	1.2	1.2	1.2	1.4	1.4	1.4	1.4	1.4	1.4
665294	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665244	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665258	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

INDIVIDUAL DOSE VOLUMES

Study [redacted] fem

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, VI 100 mg/kg												
665295	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665251	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665300	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3	1.3	1.3	1.3
665340	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665259	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665341	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665199	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665238	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665250	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665170	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665313	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665233	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665216	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665266	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665270	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665338	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665219	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665267	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665325	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665331	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665217	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665227	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665262	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665247	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665243	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665312	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665298	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665207	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665273	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665274	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665272	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665195	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665314	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665316	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665173	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

INDIVIDUAL DOSE VOLUMES

Study: [redacted] fem

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, VIII 1000 mg/kg												
665234	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665242	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665183	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665261	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665291	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665337	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665333	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665200	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665310	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665326	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665302	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665179	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665287	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665172	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665194	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665296	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665193	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665320	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665315	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665318	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665279	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665224	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665254	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665245	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665322	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665214	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665321	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665171	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665265	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665169	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665191	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665231	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665288	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665282	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665275	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665229	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3
665237	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665209	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665335	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 36	Gavage ml Day 37	Gavage ml Day 38	Gavage ml Day 39	Gavage ml Day 40	Gavage ml Day 41	Gavage ml Day 42	Gavage ml Day 43	Gavage ml Day 44	Gavage ml Day 45	Gavage ml Day 46	Gavage ml Day 47
Female, VIII 1000 mg/kg												
665303	1.1	1.1	1.1	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2
665328	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665299	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665255	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5
665213	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4
665280	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, II 0 mg/kg												
665211	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7
665271	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665178	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665317	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665230	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665225	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665174	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665319	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665221	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665278	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665176	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665283	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665297	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665301	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665269	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665220	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665334	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665257	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665175	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665336	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665192	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665232	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665307	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665246	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665289	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665264	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665185	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665206	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665306	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
665226	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665198	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665249	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665284	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665240	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665201	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665197	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665256	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665323	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665276	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, II 0 mg/kg												
665228	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7
665260	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665189	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665204	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665327	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665203	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, IV 10 mg/kg												
665308	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665215	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
665277	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665241	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665236	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665324	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665332	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665239	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665182	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665268	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665218	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665309	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665177	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665202	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665235	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665212	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665180	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665292	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8	1.8	1.8
665187	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665205	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665263	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665210	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665181	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665248	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665293	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665329	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665290	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665253	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7
665286	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665281	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665186	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665330	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665294	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665244	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665258	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

INDIVIDUAL DOSE VOLUMES

Study: [redacted] fem

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, VI 100 mg/kg												
665295	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665251	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665300	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665340	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
665259	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665341	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665199	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665238	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665250	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665170	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665313	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665233	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665216	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665266	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665270	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665338	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.1	1.1	1.1	1.1
665219	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665267	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5	1.5
665325	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.2	1.2	1.2	1.2
665331	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665217	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665227	1.4	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5	1.5
665262	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665247	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7
665243	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665312	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665298	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665207	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665273	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665274	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665272	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665195	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665314	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665316	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665173	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

INDIVIDUAL DOSE VOLUMES

Study [redacted]tem

Female, VIII 1000 mg/kg

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
665234	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5
665242	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665183	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665261	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665291	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665337	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665333	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665200	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665310	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665326	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.2	1.2	1.2	1.2
665302	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665179	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665287	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665172	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665194	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
665296	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
665193	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665320	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
665315	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665318	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665279	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665224	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7
665254	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6
665245	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665322	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665214	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665321	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665171	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665265	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665169	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665191	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665231	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665288	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665282	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665275	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665229	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
665237	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.2	1.2	1.2	1.2
665209	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4
665335	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

INDIVIDUAL DOSE VOLUMES

Study: [redacted] fem

	Gavage ml Day 48	Gavage ml Day 49	Gavage ml Day 50	Gavage ml Day 51	Gavage ml Day 52	Gavage ml Day 53	Gavage ml Day 54	Gavage ml Day 55	Gavage ml Day 56	Gavage ml Day 57	Gavage ml Day 58	Gavage ml Day 59
Female, VIII 1000 mg/kg												
665303	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3	1.3	1.3
665328	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665299	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3	1.3
665255	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665213	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665280	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, II 0 mg/kg												
665211	1.7	1.7	1.7	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
665271	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3
665178	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665317	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665230	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665225	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665174	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665319	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665221	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665278	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665176	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665283	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3
665297	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665301	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665269	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665220	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665334	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665257	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665175	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665336	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.3	1.3
665192	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665232	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665307	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665246	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665289	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665264	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665185	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
665206	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665306	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665226	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665198	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665249	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665284	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665240	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665201	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665197	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665256	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665323	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665276	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, II 0 mg/kg												
665228	1.7	1.7	1.7	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665260	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.6	1.6
665189	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665204	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665327	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665203	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, IV 10 mg/kg												
665308	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665215	1.3	1.3	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3
665277	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665241	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665236	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
665324	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665332	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665239	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665182	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665268	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665218	1.5	1.5	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665309	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665177	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665202	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665235	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.4	1.4
665212	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665180	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665292	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
665187	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665205	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665263	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665210	1.4	1.4	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665181	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665248	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665293	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665329	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665290	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665253	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665286	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665281	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665186	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.2	1.2
665330	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665294	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665244	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3
665258	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, VI 100 mg/kg												
665295	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665251	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665300	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665340	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665259	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.4	1.4
665341	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665199	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665238	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665250	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665170	1.4	1.4	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665313	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665233	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665216	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665266	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665270	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665338	1.1	1.1	1.1	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.1	1.1
665219	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665267	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665325	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665331	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665217	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665227	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665262	1.6	1.6	1.6	1.5	1.5	1.5	1.5	1.5	1.5	NM	1.6	1.6
665247	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665243	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665312	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665298	1.6	1.6	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665207	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665273	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665274	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665272	1.5	1.5	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665195	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665314	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665316	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665173	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5

Key: NM = Not Measurable; partial dose given

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, VIII 1000 mg/kg												
665234	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5
665242	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665183	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665261	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665291	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665337	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665333	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665200	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5
665310	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
665326	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665302	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665179	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665287	1.3	1.3	1.3	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.4	1.4
665172	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665194	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665296	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665193	1.6	1.6	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665320	1.3	1.3	1.3	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3
665315	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665318	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665279	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665224	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8
665254	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665245	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665322	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665214	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665321	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.3	1.3
665171	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665265	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.8	1.8
665169	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665191	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665231	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665288	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665282	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5
665275	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665229	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665237	1.2	1.2	1.2	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665209	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665335	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

INDIVIDUAL DOSE VOLUMES

Study: [redacted] fem

	Gavage ml Day 60	Gavage ml Day 61	Gavage ml Day 62	Gavage ml Day 63	Gavage ml Day 64	Gavage ml Day 65	Gavage ml Day 66	Gavage ml Day 67	Gavage ml Day 68	Gavage ml Day 69	Gavage ml Day 70	Gavage ml Day 71
Female, VIII 1000 mg/kg												
665303	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665328	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665299	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665255	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665213	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665280	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, II 0 mg/kg												
665211	1.8	1.8	1.8	1.8	1.8	1.9	1.9	1.9	1.9	1.9	1.9	1.9
665271	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665178	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665317	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665230	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665225	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665174	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665319	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665221	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665278	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665176	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665283	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665297	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
665301	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665269	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
665220	1.4											
665334	1.5											
665257	1.5											
665175	1.4											
665336	1.3											
665192	1.6											
665232	1.4											
665307	1.7											
665246	1.5											
665289	1.6											
665264	1.6											
665185	1.7											
665206	1.5											
665306	1.3											
665226	1.5											
665198	1.4											
665249	1.6											
665284	1.4											
665240	1.4											
665201	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665197	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665256	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665323	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665276	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, II 0 mg/kg												
665228	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665260	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665189	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665204	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665327	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665203	1.2											

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, IV 10 mg/kg												
665308	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665215	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665277	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665241	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665236	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665324	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665332	1.6	1.6	1.6	1.6	1.6	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665239	1.5	1.5	1.5	1.5	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665182	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665268	1.6	1.6	1.6	1.6	1.6	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665218	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665309	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665177	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665202	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665235	1.4	1.4	1.4	1.4	1.4	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665212	1.4											
665180	1.4											
665292	1.8											
665187	1.4											
665205	1.6											
665263	1.6											
665210	1.4											
665181	1.4											
665248	1.6											
665293	1.3											
665329	1.5											
665290	1.7											
665253	1.7											
665286	1.5											
665281	1.2											
665186	1.2											
665330	1.4											
665294	1.4											
665244	1.3											
665258	1.4											

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, VI 100 mg/kg												
665295	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665251	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665300	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665340	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665259	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665341	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665199	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665238	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665250	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665170	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665313	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665233	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665216	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665266	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665270	1.5	1.5	1.5	1.5	1.5	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665338	1.1											
665219	1.3											
665267	1.6											
665325	1.3											
665331	1.6											
665217	1.6											
665227	1.6											
665262	1.6											
665247	1.7											
665243	1.6											
665312	1.4											
665298	1.6											
665207	1.6											
665273	1.5											
665274	1.3											
665272	1.5											
665195	1.4											
665314	1.6											
665316	1.2											
665173	1.5											

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, VIII 1000 mg/kg												
665234	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665242	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665183	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665261	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665291	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665337	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665333	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665200	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665310	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665326	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665302	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665179	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665287	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665172	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665194	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665296	1.1											
665193	1.6											
665320	1.3											
665315	1.4											
665318	1.6											
665279	1.7											
665224	1.8											
665254	1.6											
665245	1.4											
665322	1.4											
665214	1.4											
665321	1.3											
665171	1.5											
665265	1.8											
665169	1.3											
665191	1.4											
665231	1.4											
665288	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665282	1.5	1.5	1.5	1.5	1.5	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665275	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665229	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665237	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665209	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665335	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 72	Gavage ml Day 73	Gavage ml Day 74	Gavage ml Day 75	Gavage ml Day 76	Gavage ml Day 77	Gavage ml Day 78	Gavage ml Day 79	Gavage ml Day 80	Gavage ml Day 81	Gavage ml Day 82	Gavage ml Day 83
Female, VIII 1000 mg/kg												
665303	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665328	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665299	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665255	1.6											
665213	1.5											
665280	1.7											

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Female, II 0 mg/kg									
665211	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
665271	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665178	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665317	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665230	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
665225	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.6	1.6
665174	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
665319	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665221	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665278	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665176	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665283	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665297	1.1	1.1	1.1	1.1	1.1	1.1	1.1		
665301	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665269	1.3	1.3	1.3	1.3	1.3	1.3	1.3		
665220									
665334									
665257									
665175									
665336									
665192									
665232									
665307									
665246									
665289									
665264									
665185									
665206									
665306									
665226									
665198									
665249									
665284									
665240									
665201	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665197	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665256	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665323	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665276	1.6	1.6	1.6	1.6	1.6	1.6	1.6		

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Female, II 0 mg/kg									
665228	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
665260	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
665189	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665204	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665327	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665203									

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Female, IV 10 mg/kg									
665308	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665215	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3
665277	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665241	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665236	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8	1.8
665324	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665332	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
665239	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665182	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665268	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665218	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665309	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665177	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665202	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665235	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665212									
665180									
665292									
665187									
665205									
665263									
665210									
665181									
665248									
665293									
665329									
665290									
665253									
665286									
665281									
665186									
665330									
665294									
665244									
665258									

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted] fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Female, VI 100 mg/kg									
665295	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665251	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665300	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665340	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665259	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665341	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.5	1.5
665199	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665238	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665250	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5
665170	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665313	1.7	1.7	1.7	1.7	1.7	1.7	1.7		
665233	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665216	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665266	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665270	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665338									
665219									
665267									
665325									
665331									
665217									
665227									
665262									
665247									
665243									
665312									
665298									
665207									
665273									
665274									
665272									
665195									
665314									
665316									
665173									

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Female, VIII 1000 mg/kg									
665234	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665242	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665183	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665261	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665291	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.7	1.7
665337	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4	1.4
665333	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
665200	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6
665310	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
665326	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4
665302	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665179	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665287	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665172	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665194	1.3	1.3	1.3	1.3	1.3	1.3	1.3		
665296									
665193									
665320									
665315									
665318									
665279									
665224									
665254									
665245									
665322									
665214									
665321									
665171									
665265									
665169									
665191									
665231									
665288	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665282	1.6	1.6	1.6	1.6	1.6	1.6	1.6		
665275	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665229	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665237	1.3	1.3	1.3	1.3	1.3	1.3	1.3		
665209	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665335	1.4	1.4	1.4	1.4	1.4	1.4	1.4		

Company Sanitized. Does not contain TSCA CBI

Dupont Haskell Laboratory

Study: [redacted]fem

INDIVIDUAL DOSE VOLUMES

	Gavage ml Day 84	Gavage ml Day 85	Gavage ml Day 86	Gavage ml Day 87	Gavage ml Day 88	Gavage ml Day 89	Gavage ml Day 90	Gavage ml Day 91	Gavage ml Day 92
Female, VIII 1000 mg/kg									
665303	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665328	1.5	1.5	1.5	1.5	1.5	1.5	1.5		
665299	1.4	1.4	1.4	1.4	1.4	1.4	1.4		
665255									
665213									
665280									

Company Sanitized. Does not contain TSCA CBI

Company Sanitized. Does not contain TSCA CBI

APPENDIX C

INDIVIDUAL BODY WEIGHTS

Company Sanitized. Does not contain TSCA CBI

INDIVIDUAL BODY WEIGHTS

EXPLANATORY NOTES

Critical Dates

Day 72 Last day data from the male and female rats designated for reproduction evaluations were reported with the subchronic toxicity animals. Body weights and clinical observations collected during the cohabitation and post-mating periods are reported in the Reproductive Toxicology section; Dose volumes administered during the cohabitation and post-mating periods are documented in study records.

Day 90 Last day of test substance administration for male and female rats designated for one-month and three-month recovery periods.

Day 91
- Last day of body weight and food consumption data collection for male and female rats designated for the subchronic toxicity evaluation.
- Last day of test substance administration for male rats designated for the subchronic toxicity evaluation.

Day 92
- Male rats designated for the subchronic toxicity evaluation were sacrificed.
- Last day of test substance administration for female rats designated for the subchronic toxicity evaluation.

Day 93 Female rats designated for the subchronic toxicity evaluation were sacrificed.

Day 126
- Last day of body weight and food consumption data collection for rats designated for the one-month recovery period.
- Last day of food consumption data collection for rats designated for the three-month recovery period.

Day 127 Male and female rats designated for the one-month recovery were sacrificed.

Day 182 Male and female rats designated for blood fluorine level evaluation were sacrificed.

Abbreviations

mg/kg = mg/kg/day

Note

Absence of data indicates the animal was not alive at the time of data collection.

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, I 0 mg/kg									
665047	239.6	290.5	331.3	371.1	399.5	426.4	452.8	471.2	486.1
665049	238.3	293.4	339.5	371.7	410.4	432.5	456.6	474.7	494.8
665070	280.2	352.9	405.6	443.0	487.0	537.9	561.7	587.7	615.9
665130	246.3	305.5	371.9	424.4	464.8	494.4	510.5	547.4	563.0
665076	224.9	270.7	321.1	365.0	396.1	423.4	435.2	463.2	489.2
665015	240.0	305.7	372.0	412.5	458.6	488.9	500.2	527.3	564.0
665068	253.7	314.5	366.6	416.4	449.7	472.7	476.1	500.3	515.7
665148	256.5	317.7	370.5	429.2	478.3	508.3	525.1	556.1	578.7
665016	250.3	292.8	331.2	358.2	390.6	417.0	437.1	463.3	487.6
665086	209.5	260.4	306.5	351.5	383.3	416.2	426.5	449.3	458.9
665023	241.0	308.3	364.6	410.2	445.3	485.4	498.4	514.6	532.9
665072	244.3	289.4	344.5	390.1	428.0	466.7	488.9	507.7	533.9
665151	232.9	281.2	332.8	378.4	416.1	448.4	476.1	498.5	522.9
665164	264.6	308.8	351.4	398.2	427.1	446.3	458.2	484.1	501.3
665154	236.4	301.4	347.1	407.0	443.5	476.6	501.0	532.8	550.1
665144	246.5	306.0	358.9	410.8	445.5	462.8	491.0	514.6	533.5
665104	244.0	291.9	329.5	370.5	399.0	431.1	465.5	488.4	506.4
665044	242.0	286.4	327.4	363.8	391.7	421.3	442.5	453.5	479.8
665141	208.2	251.1	292.3	331.8	360.4	391.1	414.1	431.5	453.7
665135	237.2	284.7	339.0	385.9	422.0	455.5	467.8	498.4	531.7
665005	229.3	295.1	346.1	404.5	442.9	479.3	518.5	549.1	574.0
665075	233.0	279.1	329.1	369.2	390.5	418.5	427.6	450.4	474.5
665091	240.8	307.1	363.4	418.5	461.4	498.6	525.7	563.7	589.7
665040	223.4	270.0	310.2	342.8	370.2	392.0	415.8	432.9	451.5
665069	238.3	297.7	340.6	392.1	425.2	454.4	487.0	499.6	524.7
665029	234.3	290.5	330.0	363.8	391.3	407.9	428.1	446.6	464.4
665000	238.5	297.3	339.9	380.3	415.8	435.4	461.8	485.4	498.9
665166	262.5	328.5	385.5	441.7	473.4	501.3	523.0	550.1	577.6
665012	225.2	280.6	328.2	371.6	412.5	436.1	463.7	482.8	503.2
664996	221.1	269.4	310.7	348.1	378.9	400.3	420.3	436.1	455.9
664994	243.1	296.4	345.0	389.4	410.6	432.8	448.6	464.8	478.4
665046	250.5	315.5	359.6	408.5	432.5	455.5	472.5	492.3	513.7
665021	244.2	298.1	333.8	368.6	399.6	425.1	442.4	459.3	472.5
665087	213.2	263.1	305.2	343.9	377.4	406.6	425.4	435.3	451.6
665079	249.3	312.1	366.0	415.8	461.8	496.7	520.7	547.6	572.5
665042	222.9	274.3	315.1	349.6	370.8	392.7	417.0	431.9	439.5
665098	241.7	292.6	334.2	372.4	399.3	416.9	432.8	447.8	466.9
665149	247.2	311.6	368.4	416.2	448.6	480.1	504.1	527.2	546.3
665081	237.9	291.0	330.3	368.2	394.8	415.0	433.8	451.1	472.8

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, I 0 mg/kg									
665159	243.9	303.5	350.8	395.1	435.8	460.6	485.5	500.5	522.9
665043	240.6	297.5	349.1	395.8	435.0	461.9	491.1	513.2	530.2
665064	232.5	285.3	331.8	380.0	415.9	435.2	445.7	463.9	465.1
665121	234.1	281.5	324.2	368.3	408.2	433.0	461.8	487.4	499.1
665106	259.0	316.6	360.2	407.2	443.7	472.6	496.7	533.5	541.2
665008	263.8	315.4	364.9	414.7	451.0	468.4	491.6	525.5	539.8

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, III 10 mg/kg									
665053	247.8	305.6	349.2	396.1	439.8	466.7	487.1	519.3	534.9
665074	254.2	313.9	364.5	411.5	457.6	483.8	507.3	536.0	561.8
665128	263.4	318.4	362.2	413.9	461.3	487.7	518.6	560.5	525.6
665080	240.7	301.8	355.7	400.1	430.0	468.0	482.0	504.2	525.0
664993	226.1	279.5	316.2	354.0	374.7	392.2	417.3	438.7	444.3
665131	221.7	271.7	317.2	361.5	396.6	423.6	441.7	461.5	481.6
665060	246.7	304.5	351.0	395.2	438.1	462.6	473.7	502.5	523.5
664995	254.2	300.5	348.8	390.5	425.6	443.3	450.7	472.5	476.0
665136	252.2	312.7	366.0	414.2	451.8	476.5	506.8	531.6	551.4
665033	223.3	271.6	313.1	358.0	389.8	411.0	422.3	446.9	465.6
665132	227.6	262.0	279.5	302.2	333.4	347.8	365.0	377.9	385.9
665156	239.1	300.6	342.4	386.2	424.6	446.5	468.6	495.3	513.2
665061	228.2	277.7	313.3	348.6	381.7	398.4	421.7	438.3	454.2
665145	249.8	294.2	337.7	383.0	406.6	422.3	449.1	472.9	483.0
665019	217.6	251.6	286.8	321.2	356.2	372.0	398.8	430.9	455.0
665153	240.8	297.8	336.0	381.4	419.8	442.7	453.6	477.6	494.3
665037	243.6	296.4	339.9	381.5	417.0	444.0	470.7	500.1	517.4
665163	241.9	291.5	330.0	368.0	396.7	421.7	439.1	461.4	478.6
665001	217.4	273.7	315.3	361.8	396.2	423.7	457.5	489.2	511.0
665126	243.3	288.9	321.2	349.2	379.0	408.1	439.8	461.4	481.9
665125	233.1	280.7	312.5	343.3	372.3	399.0	431.7	449.2	463.6
665017	234.6	292.9	329.0	366.8	402.8	422.6	448.2	457.9	474.4
665071	243.4	293.7	330.0	380.7	411.9	435.8	455.5	482.7	492.4
665032	225.2	266.7	303.3	340.9	379.5	399.4	412.7	436.5	447.6
664997	242.7	298.2	342.5	384.5	430.5	450.1	467.9	499.3	521.1
665110	235.2	281.2	327.1	366.3	401.3	417.9	438.9	471.8	487.3
665041	229.7	275.4	307.6	345.5	375.9	386.2	406.0	424.2	442.1
665058	257.6	307.6	353.8	396.9	442.0	466.7	494.5	521.1	537.4
665113	242.1	304.4	360.8	413.3	462.1	491.4	508.2	545.4	558.8
665056	218.9	261.0	293.4	327.4	358.8	384.8	410.5	422.8	436.1
665025	237.6	290.6	331.2	366.2	398.3	428.6	445.1	466.6	481.8
665038	253.2	310.1	355.4	392.3	432.9	459.9	481.4	504.1	521.8
665006	244.9	300.0	348.0	391.6	424.6	448.0	479.0	501.9	521.0
665167	215.0	268.1	299.7	334.1	371.6	395.8	409.7	438.1	449.1
665020	247.2	294.2	338.3	380.0	421.0	447.4	467.7	486.6	514.6

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, V 100 mg/kg									
665122	246.6	303.2	340.7	389.7	441.2	478.8	491.2	518.1	538.4
665155	244.7	308.0	359.4	404.0	443.3	481.7	489.0	504.9	531.0
665073	275.5	346.0	395.2	456.3	507.2	540.4	557.2	582.4	596.1
665089	243.9	292.9	329.8	370.1	417.5	450.6	473.4	504.7	528.3
665119	225.9	271.4	300.7	335.2	373.6	399.9	415.6	434.1	456.5
665137	225.0	280.0	325.9	369.5	399.3	435.9	444.7	443.0	477.1
665103	244.8	298.4	340.0	382.6	423.1	451.8	462.7	488.9	513.3
665143	257.4	326.3	373.5	416.4	451.4	489.8	501.0	518.3	540.5
665054	239.2	286.6	326.2	367.7	410.8	443.2	452.0	470.3	501.5
665035	215.4	258.7	290.4	322.9	351.6	375.9	385.3	401.5	411.2
665048	234.7	285.5	320.1	356.9	384.0	414.5	440.9	448.0	470.9
665030	246.1	305.6	341.8	375.4	401.3	436.6	448.1	477.9	496.1
665028	239.5	298.3	355.2	393.9	435.5	469.7	491.7	517.6	546.1
665052	252.7	320.2	361.4	405.6	435.3	467.1	484.9	504.5	525.1
665150	243.6	309.4	366.6	425.8	461.3	523.0	552.5	580.1	605.3
665116	229.8	278.0	311.0	338.2	366.9	398.7	419.3	441.6	454.3
665034	246.4	309.2	342.8	396.6	436.2	469.7	486.7	514.9	529.1
665051	239.7	299.3	332.6	365.2	398.1	422.3	436.3	453.2	464.9
665083	221.8	281.0	323.2	364.2	398.5	429.5	440.9	460.8	466.4
665124	241.4	296.0	327.9	357.6	391.5	419.8	427.7	445.1	458.8
665078	240.2	298.4	343.4	381.9	422.6	455.3	478.3	494.1	508.6
665036	227.6	281.4	313.8	348.4	374.5	396.2	416.1	432.0	437.9
665085	253.3	319.1	369.2	420.9	467.8	498.4	521.0	545.4	561.2
665092	226.0	270.2	308.5	342.5	372.2	389.2	411.0	427.0	435.5
665004	233.7	293.5	336.6	378.1	408.6	439.5	467.0	494.7	520.4
665140	231.7	288.4	326.8	367.3	400.3	431.2	454.0	475.7	495.0
665114	233.4	295.6	330.7	372.4	408.3	433.3	452.4	471.3	484.0
665139	253.0	302.4	342.4	383.4	419.0	447.3	469.2	488.9	493.5
665111	233.4	298.1	331.6	371.3	401.0	435.7	455.4	478.4	485.6
665055	229.0	283.8	330.9	371.4	409.2	438.4	458.2	473.1	485.2
665066	238.5	278.7	313.5	351.8	385.0	405.2	425.0	451.5	468.7
665039	263.6	317.3	353.0	397.3	419.4	445.6	475.8	498.1	505.2
665003	252.2	314.8	361.5	412.7	448.3	478.1	505.4	520.3	537.9
665088	214.1	255.9	283.5	319.7	348.8	370.0	386.0	402.1	422.7
665147	242.2	296.0	335.4	386.5	415.4	437.8	458.7	470.7	488.0

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, VII 1000 mg/kg									
665160	259.3	322.9	369.0	415.5	460.1	485.8	498.9	519.4	531.1
665096	242.5	300.4	343.4	387.9	421.6	456.7	478.3	502.7	522.3
665082	255.2	305.6	354.9	392.1	416.1	446.1	461.3	482.1	496.8
665107	246.9	299.1	349.8	393.9	430.6	458.3	469.1	501.4	519.7
665152	237.4	287.0	335.9	391.3	430.6	460.5	482.8	511.9	531.5
665120	228.5	272.1	308.3	349.3	371.4	399.4	409.3	438.3	457.3
664999	244.8	287.0	331.2	384.3	412.3	449.9	463.4	499.2	514.4
665026	250.5	304.6	353.6	387.4	416.5	439.0	458.3	475.4	489.0
665162	254.7	307.5	360.2	411.4	444.0	475.5	502.0	525.8	544.1
665027	230.1	283.6	326.8	373.5	405.3	429.3	438.6	467.2	485.3
665084	227.1	269.5	304.3	340.0	359.8	389.2	409.2	430.8	434.2
665142	246.5	291.8	330.8	379.2	409.5	452.4	482.3	512.5	525.5
665118	228.5	270.8	305.3	350.3	376.6	398.4	422.4	444.1	456.8
665108	262.4	308.8	352.3	403.9	432.7	451.1	475.0	493.1	492.0
665024	226.3	275.3	307.9	345.8	370.1	397.7	421.0	447.8	454.0
665050	239.8	290.2	336.5	387.3	421.5	450.8	484.3	516.9	536.0
665134	240.7	291.3	331.5	377.2	398.6	425.9	438.0	457.8	466.0
665022	235.4	280.0	309.9	331.5	348.0	365.1	388.4	399.6	402.3
665105	214.5	256.5	295.3	330.2	364.1	391.8	416.3	446.0	455.5
665102	240.1	283.3	314.2	354.0	380.2	406.6	434.5	457.0	470.0
665161	226.2	283.9	324.2	364.7	394.2	419.7	447.8	468.8	486.7
665133	233.8	279.4	327.0	386.7	417.6	440.7	466.1	500.4	501.2
665157	254.3	305.5	349.7	388.8	408.7	435.3	451.6	477.5	490.1
665093	225.4	266.2	302.3	340.2	362.2	382.7	396.5	418.7	430.2
665059	243.8	301.0	340.5	375.6	408.3	431.6	450.9	465.0	479.2
665123	246.9	297.7	353.2	399.7	441.0	468.7	489.6	514.1	528.3
665018	245.2	302.5	351.0	390.6	422.9	456.1	483.4	508.6	528.5
665065	251.6	307.9	352.8	401.4	437.7	476.9	500.9	535.8	551.3
665063	235.7	298.2	347.1	392.3	426.9	457.5	471.3	495.3	511.0
665090	229.0	265.7	310.9	355.7	381.1	401.9	427.0	452.1	467.7
665057	250.3	303.0	353.7	389.1	416.0	447.8	477.5	516.7	539.5
665011	258.3	303.2	351.9	401.6	439.8	473.7	503.3	540.5	552.7
665109	253.6	302.1	355.6	397.7	419.3	446.7	476.3	511.3	524.6
664998	211.9	256.2	293.6	334.4	361.4	394.8	413.0	431.4	448.4
665077	249.7	302.8	345.3	384.7	412.1	445.9	456.1	477.1	498.1
665158	220.9	271.3	309.0	358.7	388.6	414.6	432.0	443.9	451.2
665002	252.8	307.2	351.8	396.0	426.9	453.6	490.7	526.6	541.4
665067	238.3	287.9	339.1	384.2	407.6	442.0	459.0	481.4	494.1
665095	240.6	283.6	322.6	359.2	388.7	416.6	432.8	436.6	456.3

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Male, VII 1000 mg/kg									
665031	245.9	301.2	349.3	394.1	427.0	450.8	470.8	500.3	510.8
665146	245.3	303.4	349.4	398.6	421.1	449.4	471.8	502.2	516.6
665062	239.6	293.3	345.9	390.9	417.3	450.8	481.4	515.4	532.4
665138	218.6	266.8	300.2	339.6	366.6	395.8	415.0	434.5	445.0
665112	260.2	306.6	350.6	390.1	412.5	436.7	457.6	471.5	488.4
665007	267.1	320.9	354.6	409.1	443.7	462.3	490.0	520.1	538.3

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Male, I 0 mg/kg									
665047	505.8	517.1	535.1	546.7	553.2				
665049	521.8	537.4	552.3	557.2	569.8				
665070	651.4	662.9	686.6	703.1	725.1				
665130	577.1	600.4	614.1	615.1	628.0				
665076	505.7	516.7	528.1	526.5	531.8				
665015	602.1	615.9	627.1	647.5	653.3				
665068	539.4	569.9	585.4	600.8	605.1				
665148	595.3	614.6	633.6	644.5	655.6				
665016	511.0	527.2	541.5	555.3	565.3				
665086	486.8	497.5	497.3	504.9	513.7				
665023	553.2	575.9	590.8	593.3	590.5	602.9	603.3	613.7	618.0
665072	550.4	566.9	585.9	591.9	599.8	610.9	628.7	633.4	656.8
665151	533.6	552.4	548.2	568.3	582.5	603.2	618.3	628.3	632.9
665164	515.0	517.0	530.1	536.5	542.7	545.8	556.9	561.9	578.0
665154	570.7	585.6	598.7	610.0	609.5	616.3	623.1	626.5	647.7
665144	557.6	571.4							
665104	532.1	545.7							
665044	501.8	519.5							
665141	469.5	481.9							
665135	540.6	559.4							
665005	592.8	626.3							
665075	489.6	499.7							
665091	605.8	623.8							
665040	462.5	474.7							
665069	540.2	554.6							
665029	482.7	494.5							
665000	516.8	533.4							
665166	583.8	595.9							
665012	516.8	524.9							
664996	465.7	482.7							
664994	503.0	504.0							
665046	519.1	534.2							
665021	488.3	503.4							
665087	466.5	494.3							
665079	599.6	621.3							
665042	453.1	460.1	465.5	471.1	473.8	484.5	496.8	498.1	513.7
665098	471.3	484.2	493.1	501.7	505.7	520.2	527.7	526.5	545.2
665149	556.3	573.3	589.3	590.5	590.6	610.6	616.5	630.8	648.3
665081	479.7	493.1	503.6	508.5	503.2	516.7	531.0	543.3	553.7

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Male, I 0 mg/kg									
665159	542.6	545.6	553.3	569.0	571.5	571.6	589.4	600.1	614.7
665043	544.5	567.4	577.1	593.3	589.7	597.5	594.4	613.8	632.7
665064	474.5	482.1	487.1	495.7	501.5	514.2	533.2	529.8	552.0
665121	519.4	537.9	556.2	569.1	582.7	594.6	610.3	619.8	633.8
665106	564.0	581.3	603.8	614.4	623.2	637.1	647.2	656.2	672.9
665008	563.8	575.4	592.3	597.2	604.3	617.5	641.0	634.1	649.8

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Male, III 10 mg/kg									
665053	557.5	587.1	597.3	609.3	623.4				
665074	572.3	590.1	609.0	624.0	631.7				
665128	591.7	620.7	634.5	651.7	642.0				
665080	543.0	564.8	506.6	549.3	555.2				
664993	465.2	478.3	490.5	502.6	510.8				
665131	497.5	512.6	514.4	528.0	529.0				
665060	543.8	558.0	576.3	591.4	606.1				
664995	490.1	509.4	517.7	527.6	534.2				
665136	567.2	581.3	593.1	602.7	608.9				
665033	485.8	500.9	512.8	523.4	531.9				
665132	395.7	406.7	409.2	412.6	425.4	428.7	435.7	435.4	442.5
665156	533.4	552.2	565.4	575.3	585.9	596.8	598.2	603.4	621.8
665061	464.8	484.0	492.4	497.5	474.5	477.0	501.7	517.1	520.5
665145	492.1	512.3	522.1	522.0	522.7	523.6	537.2	541.2	551.4
665019	476.9	497.5	538.9	521.3	525.0	537.3	545.0	553.1	569.5
665153	509.2	525.8							
665037	538.9	554.0							
665163	495.4	515.8							
665001	532.7	547.6							
665126	498.9	520.0							
665125	477.3	491.5							
665017	486.5	495.1							
665071	513.6	521.3							
665032	458.4	478.8							
664997	529.4	547.4							
665110	498.6	512.5							
665041	458.8	464.4							
665058	562.2	577.9							
665113	575.6	594.0							
665056	456.3	474.9							
665025	499.1	505.3							
665038	540.4	549.3							
665006	538.9	558.7							
665167	467.0	480.6							
665020	522.2	541.3							

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Male, V 100 mg/kg									
665122	556.2	580.4	587.5	598.3	602.6				
665155	544.1	566.8	578.4	591.8	593.1				
665073	619.4	632.0	642.5	648.3	653.0				
665089	553.8	575.2	577.6	591.4	585.8				
665119	472.3	481.1	496.4	509.4	515.4				
665137	499.2	513.6	496.1	512.6	512.3				
665103	533.7	546.7	553.8	581.7	582.4				
665143	566.4	582.9	588.3	595.0	599.2				
665054	521.4	547.6	555.3	562.6	570.0				
665035	422.8	434.1	441.6	447.5	452.3				
665048	492.1	505.2	513.5	524.9	525.6	534.8	543.2	542.0	557.1
665030	512.7	523.5	533.4	548.2	552.0	556.7	572.1	574.3	591.6
665028	569.3	585.3	598.5	602.0	620.5	613.6	619.3		
665052	547.6	561.1	564.6	584.1	596.9	582.9	593.1	606.9	620.6
665150	639.6	664.9	672.9	689.8	709.4	723.2	737.9	746.1	775.6
665116	474.4	479.3							
665034	538.4	556.2							
665051	477.4	479.5							
665083	482.1	485.1							
665124	471.2	418.2							
665078	524.9	547.8							
665036	428.9	452.1							
665085	576.2	593.8							
665092	442.6	456.0							
665004	541.8	550.8							
665140	512.5	530.7							
665114	495.6	509.6							
665139	523.5	535.5							
665111	498.8	505.5							
665055	498.0	503.0							
665066	481.1	491.5							
665039	520.9	521.9							
665003	554.6	564.7							
665088	443.2	452.4							
665147	508.6	513.6							

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Male, VII 1000 mg/kg									
665160	547.1	567.4	575.8	582.9	595.9				
665096	542.9	559.0	565.2	586.1	597.7				
665082	515.6	525.7	528.8	540.8	553.3				
665107	552.9	553.0	564.0	579.3	597.5				
665152	562.8	574.1	578.9	602.3	619.2				
665120	469.2	485.9	484.1	493.0	499.6				
664999	531.4	547.8	551.8	560.6	564.2				
665026	509.6	521.1	527.9	542.1	558.2				
665162	568.4	591.7	608.3	624.8	638.6				
665027	499.0	507.6	518.5	535.0	547.5				
665084	448.7	463.3	473.5	490.8	485.0	482.5	481.4	487.4	503.9
665142	544.6	562.4	568.4	578.9	569.8	579.7	588.4	585.1	600.3
665118	474.5	494.2	493.9	509.0	508.9	511.0	530.7	534.4	545.1
665108	505.3	524.2	524.9	548.6	554.8	554.4	571.6	572.5	591.4
665024	465.4	480.4	482.0	492.5	498.8	499.3	502.1	501.4	510.2
665050	557.0	578.3							
665134	477.3	487.8							
665022	415.8	425.4							
665105	471.1	486.0							
665102	482.4	499.5							
665161	501.9	515.0							
665133	521.9	540.4							
665157	513.1	506.4							
665093	441.6	445.9							
665059	477.6	499.5							
665123	545.0	566.2							
665018	540.9	558.7							
665065	567.5	589.8							
665063	534.5	553.2							
665090	486.6	499.7							
665057	555.9	574.6							
665011	568.4	588.7							
665109	549.6	568.5							
664998	460.4	476.4							
665077	518.7	525.4							
665158	459.0	465.9	476.2	479.5	494.3	496.7	514.2	517.1	523.3
665002	560.3	575.0	589.1	603.9	612.1	615.0	625.1	631.5	644.1
665067	513.1	529.1	545.5	549.1	556.2	570.1	591.1	592.3	608.3
665095	469.6	486.0	491.0	500.1	506.6	519.8	534.2	541.3	553.8

Company Sanitized. Does not contain TSCA CBI

Study: [redacted]male

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Male, VII 1000 mg/kg									
665031	522.6	542.8	553.8	561.1	567.1	580.6	597.5	598.7	621.4
665146	531.8	551.4	568.9	576.5	578.4	593.3	601.9	605.9	619.1
665062	551.2	568.8	582.1	606.7	615.8	636.6	641.3	642.5	665.1
665138	452.5	461.9	471.4	464.3	486.1	497.5	511.0	507.5	523.6
665112	506.9	528.5	527.6	530.2	540.4	554.5	571.0	565.6	583.5
665007	564.6	582.5	593.4	604.5	628.0	636.3	645.7	648.1	655.7

Company Sanitized. Does not contain TSCA CBI

Study: [redacted]male

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Male, I 0 mg/kg									
665047									
665049									
665070									
665130									
665076									
665015									
665068									
665148									
665016									
665086									
665023	615.5	633.0	631.3	632.1	637.6	642.9	651.6	663.9	667.1
665072	659.9	686.9	701.4	705.5	723.4	736.2	745.4	756.7	766.2
665151	621.9	634.2	639.6	646.9	653.7	673.3	671.7	685.4	687.8
665164	581.0	593.6	596.3	603.8	605.8	618.0	610.5	619.0	628.7
665154	644.2	649.1	650.1	657.8	670.5	681.1	681.9	700.1	708.1
665144									
665104									
665044									
665141									
665135									
665005									
665075									
665091									
665040									
665069									
665029									
665000									
665166									
665012									
664996									
664994									
665046									
665021									
665087									
665079									
665042	514.1								
665098	543.9								
665149	642.9								
665081	550.1								

Company Sanitized. Does not contain TSCA CBI

Study: [redacted]male

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Male, I 0 mg/kg									
665159	609.9								
665043	632.6								
665064	547.9								
665121	626.2								
665106	676.4								
665008	650.0								

Company Sanitized. Does not contain TSCA CBI

Study: [redacted]male

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Male, III 10 mg/kg									
665053									
665074									
665128									
665080									
664993									
665131									
665060									
664995									
665136									
665033									
665132	439.7	451.1	452.1	456.9	460.7	469.8	465.3	471.3	470.9
665156	628.0	649.9	661.2	669.5	680.0	691.1	695.4	709.6	716.9
665061	530.5	540.4	543.8	544.2	545.1	544.3	547.5	551.8	562.5
665145	546.6	577.1	586.5	594.7	593.7	610.5	609.8	625.5	634.0
665019	569.5	595.6	597.2	593.3	600.8	610.0	617.3	627.4	643.3
665153									
665037									
665163									
665001									
665126									
665125									
665017									
665071									
665032									
664997									
665110									
665041									
665058									
665113									
665056									
665025									
665038									
665006									
665167									
665020									

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Male, V 100 mg/kg									
665122									
665155									
665073									
665089									
665119									
665137									
665103									
665143									
665054									
665035									
665048	558.5	585.8	593.0	595.9	603.5	607.7	611.5	618.1	625.9
665030	593.0	614.2	617.3	625.2	633.8	639.7	646.5	668.2	678.5
665028									
665052	624.3	643.6	645.6	643.8	650.2	671.2	668.0	686.8	696.2
665150	782.4	809.2	834.7	840.9	847.4	868.2	865.5	881.4	894.5
665116									
665034									
665051									
665083									
665124									
665078									
665036									
665085									
665092									
665004									
665140									
665114									
665139									
665111									
665055									
665066									
665039									
665003									
665088									
665147									

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Male, VII 1000 mg/kg									
665160									
665096									
665082									
665107									
665152									
665120									
664999									
665026									
665162									
665027									
665084	502.4	522.2	526.9	525.3	535.6	550.8	548.1	561.5	561.1
665142	604.7	622.7	640.8	650.4	662.0	681.3	688.0	707.5	714.2
665118	539.4	564.0	579.5	590.2	597.0	605.4	606.4	621.8	625.5
665108	597.0	607.6	610.2	608.1	608.8	620.0	626.3	631.3	636.6
665024	506.1	523.6	533.5	535.5	545.8	556.6	551.9	564.1	571.8
665050									
665134									
665022									
665105									
665102									
665161									
665133									
665157									
665093									
665059									
665123									
665018									
665065									
665063									
665090									
665057									
665011									
665109									
664998									
665077									
665158	527.9								
665002	650.8								
665067	613.7								
665095	543.5								

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] male

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Male, VII 1000 mg/kg									
665031	622.5								
665146	613.5								
665062	674.2								
665138	523.4								
665112	587.3								
665007	658.1								

Company Sanitized. Does not contain TSCA CBI

Study: [redacted]fem

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, II 0 mg/kg									
665211	185.0	206.5	228.7	264.4	282.7	293.4	305.8	326.5	344.4
665271	164.9	171.0	191.5	208.1	215.5	214.8	233.8	242.5	246.8
665178	175.5	205.7	227.1	260.8	263.5	283.5	300.5	311.5	313.6
665317	162.1	181.4	194.6	221.6	240.8	253.1	257.8	269.8	274.8
665230	185.4	203.0	229.0	254.2	276.0	284.0	280.0	302.7	311.0
665225	175.2	195.6	217.3	233.7	254.9	271.8	276.4	281.9	289.2
665174	176.0	196.5	222.2	246.5	256.8	270.1	284.0	295.1	297.0
665319	176.0	193.4	222.6	243.9	255.6	261.4	273.4	290.3	294.7
665221	185.9	210.0	231.0	255.0	266.8	290.3	271.1	289.6	284.1
665278	167.5	184.2	195.2	216.9	228.6	231.7	242.7	252.0	259.1
665176	174.8	197.6	211.3	224.7	254.6	263.6	272.5	285.0	285.1
665283	167.4	193.7	195.7	225.7	234.9	237.2	244.2	261.0	265.4
665297	147.8	152.9	165.5	185.9	192.6	195.5	206.4	211.4	212.2
665301	178.7	202.2	210.1	243.7	263.7	269.7	274.5	294.0	299.5
665269	166.3	181.3	191.7	208.2	223.9	226.7	234.9	231.3	240.0
665220	158.9	176.2	201.4	226.8	233.6	235.2	249.1	260.9	263.8
665334	191.1	204.0	229.3	253.7	270.1	277.2	292.1	293.3	299.2
665257	187.1	210.6	217.4	246.8	264.9	269.8	266.6	289.0	292.6
665175	168.4	175.1	196.9	221.2	228.2	239.4	253.3	262.9	264.6
665336	165.0	186.3	196.9	210.3	238.4	242.6	246.2	260.7	266.3
665192	185.1	193.7	228.2	247.0	261.4	262.1	284.9	298.4	300.1
665232	174.8	187.8	205.1	239.2	252.9	249.8	267.7	283.0	279.0
665307	192.1	221.3	240.0	271.0	288.3	288.1	310.5	328.1	323.0
665246	185.2	205.0	227.1	247.2	264.5	273.5	272.5	286.6	294.2
665289	173.8	200.8	222.3	240.4	262.1	273.4	282.2	289.4	296.9
665264	188.2	213.0	233.8	259.5	279.2	284.6	297.6	303.4	303.2
665185	194.1	203.3	233.2	255.7	277.4	279.7	303.0	314.2	321.2
665206	164.2	185.5	209.4	239.8	259.4	261.0	278.2	289.1	289.6
665306	164.2	183.7	199.3	210.7	225.6	239.0	250.7	247.4	259.5
665226	170.2	193.4	208.2	225.2	245.8	257.6	264.4	284.9	280.3
665198	178.7	194.0	212.9	221.1	245.9	253.5	261.2	273.2	273.1
665249	171.9	197.9	208.9	242.4	260.5	271.2	278.7	294.4	305.8
665284	171.8	196.6	217.1	242.2	254.3	259.4	272.2	273.1	274.3
665240	175.5	188.1	203.4	218.8	236.9	246.8	258.7	257.0	266.7
665201	177.7	185.7	220.0	238.2	259.6	278.8	285.1	285.7	308.3
665197	163.6	180.9	206.1	228.1	245.8	244.4	266.8	272.9	278.0
665256	153.6	183.8	202.6	224.5	230.5	253.0	264.4	270.2	272.1
665323	169.3	188.2	199.4	229.3	243.8	264.9	272.5	288.4	291.6
665276	169.1	198.3	223.2	248.4	257.0	279.4	289.4	306.5	306.8

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, II 0 mg/kg									
665228	177.0	210.3	234.6	273.7	290.8	298.0	311.7	321.4	333.6
665260	178.1	214.7	270.3	262.2	281.0	283.6	312.8	313.6	321.5
665189	180.8	221.0	271.3	264.3	293.8	293.9	296.4	312.0	313.9
665204	182.2	207.1	217.6	237.6	251.4	259.8	263.8	271.9	273.2
665327	160.1	189.5	203.4	225.9	232.5	251.9	252.3	263.1	272.5
665203	153.9	171.9	180.3	203.2	217.2	220.9	230.0	236.2	241.6

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, IV 10 mg/kg									
665308	195.0	212.2	223.7	258.2	274.1	283.6	291.0	296.1	312.5
665215	156.9	161.0	184.9	213.4	219.8	222.1	238.8	244.2	250.2
665277	172.3	197.2	217.4	228.5	236.9	255.7	272.8	273.7	273.6
665241	161.3	177.7	202.4	220.9	236.7	237.2	251.0	262.9	263.8
665236	187.6	218.0	235.1	264.1	281.9	295.5	295.8	318.2	323.3
665324	173.8	197.5	212.4	229.3	247.3	260.1	262.4	258.8	268.4
665332	181.1	212.0	236.7	252.9	279.6	287.8	297.5	304.8	311.6
665239	176.7	199.3	219.3	238.6	253.0	264.1	266.0	272.1	284.5
665182	163.8	189.5	203.2	225.8	251.1	244.5	267.9	282.6	275.8
665268	167.2	185.9	217.2	236.6	256.9	274.6	268.9	286.8	295.3
665218	175.0	188.2	209.7	232.1	248.3	251.5	274.5	284.3	291.3
665309	167.3	192.7	204.7	236.8	256.0	262.8	269.8	283.3	285.1
665177	177.1	203.4	220.9	222.5	251.4	265.6	271.0	264.2	281.3
665202	171.9	183.7	204.4	226.8	240.2	244.3	261.5	268.3	275.7
665235	161.1	188.0	204.9	228.0	248.8	256.7	266.4	277.8	283.1
665212	155.8	181.7	198.1	215.5	236.5	241.8	253.2	264.5	265.9
665180	168.8	193.9	201.0	223.3	237.6	247.3	257.0	256.4	264.3
665292	203.5	226.9	238.9	279.0	301.4	307.5	323.6	348.7	351.9
665187	152.9	183.0	196.6	226.4	238.2	246.2	259.9	276.3	281.2
665205	190.6	213.5	231.1	268.2	277.4	283.9	293.2	308.1	314.1
665263	174.7	203.4	216.6	254.6	279.4	284.1	304.8	310.2	320.8
665210	170.3	180.9	204.2	231.8	241.1	244.4	262.2	271.7	272.0
665181	182.3	199.0	222.7	248.0	254.4	268.0	273.5	279.6	282.1
665248	184.0	217.7	233.4	265.5	283.6	294.7	312.0	301.5	320.9
665293	171.0	195.6	211.1	229.8	244.4	242.7	256.6	255.1	259.7
665329	191.4	211.3	232.5	252.0	271.4	275.0	292.2	297.1	307.2
665290	191.0	224.5	250.6	281.5	297.3	313.2	320.6	333.2	342.6
665253	200.3	219.5	254.0	273.8	302.9	317.3	324.0	329.4	340.7
665286	158.7	180.9	199.1	217.9	225.9	246.7	258.5	273.2	281.8
665281	154.0	174.9	187.6	200.4	200.4	218.9	225.2	226.9	225.4
665186	160.0	178.6	196.2	209.2	225.4	227.8	233.1	237.4	245.1
665330	171.5	203.6	206.0	234.7	243.1	245.3	274.6	279.7	285.2
665294	157.9	183.2	192.8	218.3	241.5	256.5	260.2	263.5	275.6
665244	143.4	147.9	174.8	199.8	208.1	214.4	228.1	235.7	239.3
665258	174.3	195.4	209.4	229.3	240.9	241.7	260.7	268.6	276.2

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, VI 100 mg/kg									
665295	189.5	222.2	236.8	251.9	275.0	288.9	299.6	309.9	324.4
665251	161.8	174.1	204.7	220.7	232.1	246.5	249.9	268.5	270.6
665300	178.7	197.2	216.2	243.2	262.9	271.1	267.6	289.2	290.3
665340	157.1	182.2	199.2	212.9	216.7	227.1	234.9	247.6	251.8
665259	173.3	198.1	211.2	238.1	255.3	263.6	260.6	274.1	282.5
665341	187.3	213.8	226.2	243.5	261.0	266.7	277.8	286.5	297.8
665199	171.2	191.2	207.4	236.3	252.6	261.6	268.2	288.7	292.7
665238	182.6	206.1	229.3	243.6	270.2	283.7	280.6	280.0	296.7
665250	169.8	194.5	202.4	228.7	242.6	251.5	250.8	270.8	270.6
665170	163.3	177.3	197.7	223.4	240.5	247.4	255.8	270.3	271.9
665313	184.8	197.3	230.8	237.6	274.4	274.5	297.1	295.4	307.4
665233	177.0	196.8	214.4	232.2	256.2	270.6	282.1	279.0	292.7
665216	169.8	188.3	202.2	234.2	259.3	263.4	270.1	290.7	291.1
665266	175.1	196.6	204.8	212.6	231.6	232.0	233.0	244.2	249.2
665270	171.3	185.1	212.9	232.7	242.2	259.9	272.9	276.2	284.3
665338	142.1	160.2	174.0	176.4	197.8	204.9	208.9	207.7	218.6
665219	165.9	182.9	186.1	219.2	229.8	239.5	242.8	254.7	263.9
665267	184.2	211.0	230.7	250.3	264.4	288.1	298.3	311.0	305.5
665325	159.5	178.2	196.2	210.3	217.7	227.9	242.4	253.1	246.9
665331	174.5	191.1	213.2	235.7	254.3	266.7	273.9	293.9	303.3
665217	178.2	199.5	224.2	248.6	264.9	271.0	279.9	295.7	302.3
665227	170.6	196.2	221.1	247.6	260.1	275.5	283.0	312.3	304.0
665262	177.3	209.7	225.1	252.4	270.0	288.0	304.7	293.6	311.5
665247	191.7	211.2	220.0	243.4	264.3	278.0	292.1	314.6	332.3
665243	177.9	203.8	223.9	240.6	257.7	265.4	285.1	296.6	296.4
665312	168.3	189.5	201.6	214.8	232.7	235.6	247.7	251.5	262.8
665298	194.5	222.1	238.0	256.5	272.3	272.4	293.2	292.9	310.4
665207	205.0	225.2	252.3	278.1	292.5	291.3	303.3	308.8	312.7
665273	170.1	191.2	218.5	242.0	261.2	262.9	278.8	284.6	294.6
665274	165.2	186.5	202.3	219.5	228.9	239.4	248.0	256.1	258.9
665272	172.3	189.8	217.5	233.2	249.3	255.6	272.6	277.4	290.6
665195	187.3	198.6	209.9	233.6	248.9	251.7	256.8	272.8	277.7
665314	174.2	193.1	220.8	246.6	267.0	271.6	301.5	302.2	309.3
665316	154.8	179.3	188.6	209.4	218.8	224.9	222.9	232.2	239.1
665173	176.1	204.5	219.8	246.8	258.2	263.9	270.1	286.3	291.0

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female,, VIII 1000 mg/kg									
665234	183.0	209.5	218.8	233.4	255.9	275.2	275.3	278.9	294.9
665242	165.0	191.7	215.4	236.7	250.9	257.1	267.3	265.1	281.9
665183	169.5	183.4	200.9	227.8	236.5	240.6	253.8	263.0	265.0
665261	163.7	195.4	216.6	238.1	245.7	271.9	280.8	302.4	301.9
665291	186.6	208.2	229.2	252.7	263.7	279.2	283.5	305.0	300.3
665337	165.0	181.7	187.5	207.4	224.3	234.1	234.1	251.9	256.5
665333	172.7	196.3	199.8	227.6	237.8	246.9	242.9	268.7	271.5
665200	178.3	206.8	231.9	253.5	274.8	285.8	289.6	299.4	309.5
665310	183.9	205.9	226.4	244.7	272.5	289.9	294.5	308.7	310.7
665326	159.4	188.4	199.7	214.7	215.7	235.2	239.9	250.4	244.5
665302	159.8	180.9	195.0	213.9	226.6	227.4	248.6	253.3	260.5
665179	170.4	198.3	223.1	237.1	255.6	264.1	278.3	278.6	282.2
665287	164.7	189.8	206.5	227.1	241.0	242.9	261.1	264.3	269.6
665172	175.3	200.6	215.2	232.9	252.8	256.0	268.7	273.6	275.9
665194	155.9	176.1	176.1	202.4	210.7	223.6	239.2	234.9	257.6
665296	152.4	157.7	161.8	178.3	189.9	191.8	190.6	197.2	207.9
665193	191.5	214.1	231.8	257.9	267.0	290.5	292.2	299.7	310.5
665320	163.0	180.9	179.5	214.3	223.5	235.9	241.1	248.4	258.4
665315	165.7	175.4	184.3	205.4	223.6	231.3	244.5	256.9	254.7
665318	179.6	206.7	221.7	242.2	264.0	274.0	287.1	301.8	311.5
665279	176.8	200.5	228.6	253.8	278.1	295.9	307.6	329.4	327.6
665224	187.3	214.0	236.9	258.3	281.2	287.9	303.8	318.3	332.2
665254	183.8	199.9	228.5	256.5	269.5	280.8	296.4	304.8	317.2
665245	170.2	190.4	212.7	224.9	248.2	250.1	264.4	273.0	279.4
665322	177.9	200.0	210.6	223.5	238.3	250.9	258.8	263.4	272.6
665214	183.8	208.7	224.2	243.4	255.6	267.3	273.8	270.6	282.4
665321	152.8	163.0	181.8	198.9	210.6	212.9	231.6	239.2	241.6
665171	169.4	193.1	216.4	238.1	250.6	265.2	277.5	289.6	285.6
665265	194.6	217.8	244.4	277.2	298.1	312.9	324.0	339.1	349.4
665169	153.0	176.2	191.5	209.6	231.6	241.0	245.1	255.3	261.7
665191	151.4	181.0	190.7	218.4	241.9	243.3	260.9	267.5	286.0
665231	160.8	183.5	204.1	218.3	230.1	245.2	254.6	256.7	265.4
665288	177.4	207.5	216.6	253.7	269.9	282.7	277.7	300.7	301.2
665282	186.1	218.5	235.2	249.3	263.5	278.6	292.3	302.1	296.9
665275	158.0	174.9	197.2	219.0	230.6	234.1	257.0	266.7	264.6
665229	152.3	180.4	202.2	221.9	238.4	239.0	256.4	247.2	262.6
665237	157.5	173.2	195.4	219.6	228.9	232.9	243.3	252.3	249.0
665209	165.1	186.0	205.8	225.9	244.5	246.9	247.8	267.2	270.2
665335	167.4	191.6	215.8	231.1	242.7	248.7	260.7	271.9	273.3

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 0	Body Weight g Day 7	Body Weight g Day 14	Body Weight g Day 21	Body Weight g Day 28	Body Weight g Day 35	Body Weight g Day 42	Body Weight g Day 49	Body Weight g Day 56
Female, VIII 1000 mg/kg									
665303	165.7	189.1	185.3	213.7	225.3	227.5	236.3	249.5	252.8
665328	172.5	196.7	213.3	240.2	246.2	254.0	270.6	283.3	289.8
665299	169.9	200.2	215.8	228.4	238.3	250.2	260.3	270.3	268.6
665255	190.2	205.0	226.1	260.1	272.5	275.2	295.7	300.2	305.7
665213	174.2	192.6	214.8	248.1	248.6	268.2	272.6	280.6	274.6
665280	182.8	210.4	223.9	261.9	272.2	290.4	294.3	314.3	324.6

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Female, II 0 mg/kg									
665211	350.0	357.6	374.2	377.3	383.1				
665271	248.6	262.5	267.9	263.9	268.1				
665178	319.3	322.7	339.1	339.0	346.4				
665317	281.0	287.0	292.2	300.9	304.4				
665230	312.5	313.3	321.8	327.6	332.7				
665225	294.8	299.2	296.6	305.5	316.7				
665174	310.9	323.5	326.0	320.0	336.5				
665319	297.7	300.5	308.5	311.6	314.9				
665221	302.3	290.0	299.2	312.6	327.3				
665278	268.0	272.1	284.5	281.1	288.7				
665176	291.8	296.3	310.7	309.1	320.7	314.5	345.1	356.5	349.8
665283	270.5	266.8	277.6	278.1	277.4	279.3	287.5	296.5	287.3
665297	211.3	214.8	216.3	220.3	227.9	234.7	236.9	240.1	242.5
665301	305.7	295.9	307.8	326.0	322.4	332.4	332.9	341.2	348.0
665269	249.3	249.9	240.7	252.1	257.1	249.6	260.6	274.4	277.8
665220	268.7	276.5							
665334	304.7	307.3							
665257	297.3	295.0							
665175	271.1	277.2							
665336	271.5	269.7							
665192	306.2	323.8							
665232	272.5	287.7							
665307	331.8	340.8							
665246	294.0	298.5							
665289	300.5	312.5							
665264	304.7	310.7							
665185	316.3	334.0							
665206	284.8	300.8							
665306	269.6	266.2							
665226	299.0	294.0							
665198	277.0	278.6							
665249	314.8	313.3							
665284	276.2	280.3							
665240	275.4	275.5							
665201	321.2	312.9	307.6	321.8	325.6	325.1	330.5	342.0	344.7
665197	272.1	285.9	291.5	294.8	292.2	300.1	311.2	309.3	309.0
665256	286.9	294.2	290.5	288.9	296.4	303.6	303.0	305.6	312.9
665323	297.3	313.1	308.0	315.7	318.7	329.7	330.5	332.6	349.8
665276	312.0	315.5	313.5	318.3	333.6	320.5	336.3	336.5	356.8

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Female, II 0 mg/kg									
665228	314.4	327.3	333.5	339.5	336.4	343.2	352.8	355.7	387.8
665260	331.2	328.6	334.3	348.4	357.2	370.5	400.8	406.2	414.3
665189	321.9	327.6	319.4	324.6	324.1	319.2	338.1	338.8	337.3
665204	279.0	275.6	289.6	290.7	287.5	287.9	290.9	304.0	303.9
665327	274.4	272.0	279.7	291.0	289.1	284.1	299.4	302.8	296.8
665203	242.3	242.5							

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Female, IV 10 mg/kg									
665308	317.0	311.7	325.0	321.6	322.8				
665215	243.5	258.7	253.9	262.2	251.4				
665277	280.5	291.4	295.0	290.5	298.6				
665241	277.1	284.5	284.6	286.3	287.2				
665236	318.0	335.2	342.1	353.4	352.0				
665324	288.9	277.2	276.8	290.5	294.7				
665332	321.6	321.0	334.7	328.4	337.9				
665239	283.5	290.0	286.7	292.1	299.8				
665182	286.5	295.3	291.9	299.0	307.3				
665268	305.5	310.1	299.8	311.0	316.7				
665218	284.2	305.2	307.8	314.4	303.5	317.3	322.0	329.0	336.8
665309	293.4	298.3	305.4	314.4	312.1	318.1	341.5	345.8	346.0
665177	289.0	286.4	281.2	281.7	301.0	299.9	303.5	306.3	323.1
665202	276.8	292.0	299.0	305.7	300.0	307.9	315.2	322.3	315.7
665235	291.9	286.0	265.2	293.9	295.5	297.3	305.1	310.7	304.4
665212	276.1	282.2							
665180	276.6	281.3							
665292	356.4	359.2							
665187	282.0	287.3							
665205	321.8	319.3							
665263	321.2	325.9							
665210	269.7	277.6							
665181	284.6	284.5							
665248	328.5	325.5							
665293	260.9	265.7							
665329	299.2	304.9							
665290	347.2	347.3							
665253	336.2	333.4							
665286	293.3	295.3							
665281	235.4	235.7							
665186	250.4	245.3							
665330	287.0	287.5							
665294	281.5	275.7							
665244	247.4	261.2							
665258	286.6	279.9							

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Female, VI 100 mg/kg									
665295	334.5	335.3	339.5	341.0	339.9				
665251	270.6	287.2	290.2	298.6	295.8				
665300	299.1	301.4	310.6	315.6	318.6				
665340	260.1	269.4	274.5	271.5	286.8				
665259	291.8	288.2	298.6	300.3	301.1				
665341	304.5	304.4	303.0	310.3	308.6				
665199	291.0	293.0	300.0	304.4	305.8				
665238	300.5	306.0	299.9	310.3	315.4				
665250	277.9	278.3	281.7	285.3	292.5				
665170	252.1	273.6	286.5	286.3	288.9				
665313	314.2	320.4	316.5	336.5	343.2	341.0	348.3	351.5	357.5
665233	300.7	304.4	306.8	310.7	324.1	322.5	323.3	342.9	345.8
665216	299.8	292.5	296.9	307.5	300.9	309.5	331.9	333.3	329.6
665266	256.1	256.3	260.4	270.3	273.1	276.3	295.9	291.3	292.6
665270	289.0	294.1	287.7	300.4	301.0	301.4	313.5	323.9	325.6
665338	231.6	225.1							
665219	269.6	265.6							
665267	325.5	325.5							
665325	256.0	261.0							
665331	311.8	310.7							
665217	301.0	310.4							
665227	317.5	318.8							
665262	304.0	316.0							
665247	340.4	336.5							
665243	307.4	323.2							
665312	274.0	271.2							
665298	309.5	315.2							
665207	312.3	321.2							
665273	301.9	301.4							
665274	262.4	268.1							
665272	287.8	292.5							
665195	276.3	274.5							
665314	314.0	322.4							
665316	241.4	241.1							
665173	297.1	296.1							

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Female, VIII 1000 mg/kg									
665234	312.8	309.2	308.8	321.5	328.9				
665242	285.5	293.7	293.7	295.2	302.6				
665183	265.8	276.1	281.0	278.5	279.2				
665261	301.6	302.1	316.0	325.3	328.1				
665291	317.0	319.9	321.8	321.3	330.7				
665337	267.7	266.9	278.3	287.9	285.8				
665333	275.5	279.0	293.8	295.9	302.2				
665200	311.2	309.0	323.3	322.6	329.6				
665310	326.1	344.0	337.0	349.0	349.9				
665326	263.1	260.6	272.2	266.4	277.2				
665302	265.7	283.0	288.9	293.2	292.0	292.3	308.1	315.9	318.6
665179	291.1	291.7	298.2	300.8	309.7	312.8	316.2	325.1	323.3
665287	295.9	283.1	301.5	296.5	296.5	286.2	313.9	310.6	312.7
665172	284.3	285.7	287.8	295.6	296.9	296.7	309.9	316.4	317.1
665194	259.5	266.5	262.8	269.4	277.6	282.8	294.8	312.5	305.6
665296	217.1	221.1							
665193	304.5	323.3							
665320	248.8	268.6							
665315	260.5	270.0							
665318	315.4	322.4							
665279	332.5	341.0							
665224	346.1	356.1							
665254	320.4	320.4							
665245	288.1	284.6							
665322	275.9	275.0							
665214	281.5	285.1							
665321	233.9	250.6							
665171	300.3	296.1							
665265	341.3	361.3							
665169	263.0	266.6							
665191	282.6	289.4							
665231	258.8	272.7							
665288	307.1	305.7	312.4	318.6	318.5	322.3	332.0	335.8	350.5
665282	312.2	306.8	319.3	318.4	329.4	337.1	352.6	353.5	351.4
665275	266.8	276.2	279.1	279.8	267.6	284.6	294.4	304.3	313.9
665229	274.6	274.4	270.7	282.8	284.8	286.0	288.0	300.8	293.3
665237	250.7	256.8	267.7	265.3	266.8	274.6	283.8	278.6	275.7
665209	278.7	276.5	282.7	291.8	280.6	292.9	304.5	300.7	312.0
665335	277.4	280.0	288.9	288.9	290.5	300.2	307.4	308.4	313.7

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 63	Body Weight g Day 70	Body Weight g Day 77	Body Weight g Day 84	Body Weight g Day 91	Body Weight g Day 98	Body Weight g Day 105	Body Weight g Day 112	Body Weight g Day 119
Female, VIII 1000 mg/kg									
665303	255.7	268.8	275.0	272.3	269.4	277.2	288.1	296.0	293.6
665328	288.0	301.7	303.5	308.3	305.9	318.7	329.3	355.6	334.2
665299	277.5	286.6	280.0	278.9	280.0	287.8	288.2	292.1	295.5
665255	306.1	318.2							
665213	293.5	306.6							
665280	325.5	339.0							

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Female, II 0 mg/kg									
665211									
665271									
665178									
665317									
665230									
665225									
665174									
665319									
665221									
665278									
665176	363.8	374.7	375.7	383.3	376.4	401.6	385.7	394.2	391.9
665283	284.5	288.3	287.3	287.4	293.9	295.0	288.8	288.6	296.1
665297	248.0	254.4	261.5	253.5	246.8	254.1	252.0	258.8	262.5
665301	349.4	357.2	375.1	379.2	387.0	403.5	399.8	410.9	413.8
665269	273.2	268.7	280.6	277.7	280.0	280.8	289.7	284.7	292.8
665220									
665334									
665257									
665175									
665336									
665192									
665232									
665307									
665246									
665289									
665264									
665185									
665206									
665306									
665226									
665198									
665249									
665284									
665240									
665201	346.7								
665197	315.3								
665256	320.2								
665323	345.2								
665276	352.4								

Company Sanitized. Does not contain TSCA CBI

Study: [redacted]fem

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Female, II 0 mg/kg									
665228	384.2								
665260	417.0								
665189	346.8								
665204	309.9								
665327	296.4								
665203									

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Female, IV 10 mg/kg									
665308									
665215									
665277									
665241									
665236									
665324									
665332									
665239									
665182									
665268									
665218	352.1	354.6	356.5	351.1	363.5	382.5	378.6	380.9	391.4
665309	344.2	355.5	353.3	361.2	355.1	374.7	371.5	372.6	370.5
665177	322.9	321.2	340.0	336.0	335.8	336.0	335.9	339.9	353.6
665202	326.2	331.2	334.0	333.0	344.2	350.5	345.7	350.7	356.2
665235	302.2	309.2	315.5	307.7	312.8	324.6	318.8	326.0	328.7
665212									
665180									
665292									
665187									
665205									
665263									
665210									
665181									
665248									
665293									
665329									
665290									
665253									
665286									
665281									
665186									
665330									
665294									
665244									
665258									

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Female, VI 100 mg/kg									
665295									
665251									
665300									
665340									
665259									
665341									
665199									
665238									
665250									
665170									
665313	356.1	368.9	382.4	372.0	380.9	390.2	380.4	391.8	396.1
665233	348.8	349.0	368.8	368.7	366.6	376.7	367.8	383.3	377.9
665216	330.8	341.8	349.2	348.3	348.7	360.1	364.0	362.5	367.5
665266	287.9	301.3	305.7	309.1	313.6	316.3	314.1	310.2	322.2
665270	330.9	344.7	348.1	343.2	352.0	363.2	363.4	371.8	376.7
665338									
665219									
665267									
665325									
665331									
665217									
665227									
665262									
665247									
665243									
665312									
665298									
665207									
665273									
665274									
665272									
665195									
665314									
665316									
665173									

Company Sanitized. Does not contain TSCA CBI

Study: [redacted] fem

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Female, VIII 1000 mg/kg									
665234									
665242									
665183									
665261									
665291									
665337									
665333									
665200									
665310									
665326									
665302	316.5	314.5	320.8	333.0	336.9	340.6	349.4	350.3	352.7
665179	335.9	336.2	342.8	341.7	341.1	357.9	358.4	364.0	368.8
665287	320.0	317.0	324.2	337.2	341.0	355.4	353.7	366.3	375.8
665172	316.4	323.7	333.7	323.0	332.3	343.9	346.9	358.6	354.5
665194	309.3	327.3	328.4	331.2	327.3	340.9	338.1	342.6	351.5
665296									
665193									
665320									
665315									
665318									
665279									
665224									
665254									
665245									
665322									
665214									
665321									
665171									
665265									
665169									
665191									
665231									
665288	342.7								
665282	366.4								
665275	306.9								
665229	301.1								
665237	290.2								
665209	302.0								
665335	312.5								

Company Sanitized. Does not contain TSCA CBI

Study: [redacted]fem

Individual Body Weights

	Body Weight g Day 126	Body Weight g Day 133	Body Weight g Day 140	Body Weight g Day 147	Body Weight g Day 154	Body Weight g Day 161	Body Weight g Day 168	Body Weight g Day 175	Body Weight g Day 182
Female, VIII 1000 mg/kg									
665303	290.9								
665328	329.3								
665299	294.9								
665255									
665213									
665280									

Company Sanitized. Does not contain TSCA CBI